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CHAPTER 1 : Introduction 
 
1.1 General Overview 
 
The arachidonate or eicosanoid cascade produces oxygenated metabolites, 
which are derived from arachidonic and related fatty acids through a series of 
complex interrelated biosynthetic pathways.  Arachidonic acid (AA) is a 
polyunsaturated fatty acid found in the membrane phospholipids (especially 
phosphatidylethanolamine, phosphatidylinositides, and phosphatidylcholine) of 
the body's cells, and is abundant in the brain, muscles, and liver.  The first step in 
the biosynthesis is the production of free arachidonic acid in tissues from 
membrane phospholipids upon stimulation of the enzyme phospholipase A2 by 
various physiological and pathological factors, including hormones and cytokines 
as well as eicosanoids (Murakami, Nakatani et al. 1997; Fitzpatrick and 
Soberman 2001).  Eicosanoids are lipid mediators that are involved in many 
homeostatic biological functions and inflammation (Funk 2001).  The three main 
pathways for eicosanoid metabolism, involve cyclooxygenases (COXs), 
lipoxygenases (LOXs) and epoxygenases or the cytochrome P-450 (CYP-450) 
(Needleman, Turk et al. 1986; Spector, Gordon et al. 1988; Serhan 1994).  The 
cyclooxygenase pathway (COX-1 and COX-2, two major isoforms) generates 
PGG2 and PGH2, which get converted further to other prostaglandins, 
prostacyclin and thromboxanes (TXs) (Samuelsson, Goldyne et al. 1978; Smith, 
Marnett et al. 1991).  Lipoxygenases  are named  depending upon the insertion 
of molecular oxygen at  different  predominant positions on the arachidonic acid, 
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mainly 5, 12 and 15, but also 8-lipoxygenase is relevant in cancer for production 
of various hydroperoxyeicosatetraenoic acids (HPETEs), which are converted by 
peroxidases into hydroxyeicosatetraenoic acids (HETEs) and other products 
(Hammarstrom 1983; Samuelsson 1983; Samuelsson, Dahlen et al. 1987; Brash 
1999).  For example, 5-HETE yields, leukotriene LTA4, which is in turn  a 
precursor for LTΒ4, cysteinyl-leukotrienes (CysLTs) and lipoxins (LXs) 
(Samuelsson, Dahlen et al. 1987).  The cytochrome P-450 epoxygenase 
pathway produces epoxy eicosatetraenoic acids (EpETrE).  Many of the essential 
enzymes, precursors and products are cell type specific (Fitzpatrick and Murphy 
1988; Fisslthaler, Popp et al. 1999)  
 
Figure 1.1: Arachidonic Acid Pathway 
Source:  Aliment Pharmacol Ther 18(11):1049-1069, 2003 
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Lipoxygenases comprise a group of non-heme iron dioxygenases that catalyze 
oxidation of polyunsaturated fatty acids in animals and plants (Yamamoto 1992; 
Brash 1999; Kuhn and Thiele 1999).  Lipoxygenases insert molecular oxygen 
with regional specificity into arachidonic acid at  C-5, C-12, and C-15 of 
arachidonic acid, respectively generating various hyperperoxides  (Brash 1999). 
So far three major lipoxygenases are identified in mammalian tissue i.e. 5-, 12-, 
15-lipoxygenases depending on the predominant position of insertion of 
molecular oxygen in arachidonic acid  moiety (Brash 1999).  Arachidonic acid is 
metabolized by 5-LOX to hydroperoxyeicosatetraenoic acid (5-HPETE) which 
subsequently gets converted to 5-HETE and leukotrienes.  
12-lipoxygenase metabolizes AA to 12-HPETE, which is eventually 
transformed to 12(S)-hydroeicosatetranoic acid, or 12(S)-HETE.  Similarly 15-
LOX-1 and 15-LOX-2 isoforms generate 15-HPETE, which is ultimately 
converted to 15-HETE and lipoxins (Figure 1.1).  8(R)-lipoxygenase and 8(S)-
lipoxygenase have been cloned from mouse skin and coral plexaura homomalla 
respectively (Brash, Boeglin et al. 1996). The metabolites of all the 
lipoxygenases have been reported to potentially form signaling lipid mediators 
that exert their effects through G protein–coupled receptors (GPCR) (Brash 
1999; Serhan, Gotlinger et al. 2004; Guo, Zhang et al. 2011).  These 
Lipoxygenases are expressed predominantly in specific tissues.  For example, 5-
LOX is expressed in higher amounts in polymorphonuclear leukocytes (Funk, 
Hoshiko et al. 1989; Funk, Furci et al. 1991), and 15-LOX is expressed in 
reticulocytes during anemia (Rapoport, Schewe et al. 1979; Fleming, Thiele et al. 
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1989), whereas 12-LOX is expressed constitutively by platelets (Chen and Funk 
1993).  However, the distinction between 12- and 15-LOXs becomes blurred with 
respect to some isoenzymes (e.g. leukocyte-type 12-LOX) due to the multiple 
sites of oxidation on arachidonic acid (Yamamoto, Suzuki et al. 1997). 
1.2 12-Lipoxygenase 
 
To date, three isoforms of 12-LOX have been identified in humans accordingly to 
their origin or cell type: epidermis, leukocyte, and platelet (Yoshimoto and 
Takahashi 2002).  These are distinct enzymes by sequence catalytic properties, 
and function (Yamamoto, Suzuki et al. 1997; Limor, Weisinger et al. 2001; 
Siebert, Krieg et al. 2001).  Platelet type 12-LOX is absent in normal tissues or is 
expressed at a lower level in normal tissues compared to cancer cells.  The 
human platelet-type 12-LOX has been cloned from human erythroleukemia cells 
and is found primarily in human platelets, but also in epithelial cells, 
megakaryocytes, keratinocytes, umbilical vein endothelial cells and several tumor 
cells.  Platelet type 12-LOX metabolizes C-20 fatty acids, such as AA to form 
exclusive product 12(S)-HETE (Kitt, Park et al. 1988; Funk, Funk et al. 1992; 
Krieg, Kinzig et al. 1995).  Another LOX, a porcine leukocyte type 12-LOX that 
has been isolated and cloned from porcine leukocytes, porcine pituitary cells, and 
bovine tracheal cells, metabolizes both AA to give 12(S)-HETE and small 
amounts of 15(S)-HETE and linoleic acid to15(S)-HETE (Limor, Weisinger et al. 
2001).  There is evidence for the presence of a leukocyte-type 12-LOX in human 
adrenal glomerulosa cells.  A third type termed  epithelial-type 12-LOX has been 
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cloned from  bovine tracheal epithelial cells and shares more homology with 
leukocyte 12-LOX and 15-LOX than with platelet type 12-LOX and catalyzes the 
formation of both 12(S)-HETE and 15(S)-HETE.  Additionally, a structural class 
of mammalian lipoxygenases has been identified as epidermis-derived 
lipoxygenase-3 (ALOXE3), and an epidermal 12(R)-LOX was cloned from human 
skin and shares 54% homology to each other.  No enzymatic activity has been 
detected by using linoleic or arachidonic acids as substrates for 12(R)-LOX 
(Krieg, Kinzig et al. 1995). (Figure 1.2, Phylogenetic tree of mammalian 
lipoxygenases;  
 
Figure 1.2:  Phylogenetic tree of mammalian lipoxygenases. 
Source: http://www.glycosciences.de/spec/lox-db/lipoxygenase-info) 
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 Lipoxygenase protein is a single polypeptide chain.  The molecular mass 
of the 12-LOX protein  is 75-81 kDa (≈662-711 amino acids) in mammals and 94-
103 kDa (≈838-923 amino acids) in plants (Shibata and Axelrod 1995; Brash 
1999).  LOX are members of a multi-gene family exhibiting an overall sequence 
identity of ≈ 25-40%, while close functional homologues across species share 70-
95% identity (LOX-Dbase).  12-LOX genes from porcine, human and murine 
sources have been isolated from genomic libraries (Yoshimoto, Yamamoto et al. 
1990; Funk, Funk et al. 1992; Yamamoto 1992).  They have a highly conserved 
structure of 14 exons and 13 introns.  12-LOX proteins are comprised of highly 
conserved domains and sequence motifs that are important for their unique 
structure and also for binding of catalytic iron (His-X4-His-X4-His-X17-His-X8-His). 
Plant and mammalian lipoxygenase alignment reveals two domains; the PLAT 
(Polycystin-1, lipoxygenase, Alpha-Toxin) domain at the N-terminus or LH2 
(Lipoxygenase homology) domain, and a catalytic C-terminal part (Ivanov, Di 
Venere et al. 2011).  Iron binds to the 3 conserved histidines, one His/Asn/Ser, 
and isoleucine at the C-terminus in an octahedral arrangement (LOX-Dbase) 
(Minor, Steczko et al. 1996).  All mammalian lipoxygenases are homologous, 
which indicates that they have a common ancestral gene origin.  All human LOX 
are localized to the sub-band at p13.1 of chromosome 17 with the exception of 5-
LOX (Funk, Funk et al. 1992).  Among all the LOX metabolites, 12(S)-HETE, the 
sole product of platelet type 12-LOX metabolism of AA, promotes the most 
divergent biological functions such as stimulating endothelial retraction, actin 
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polymerization, tumor cell adhesion, motility, invasion and metastasis (Timar, 
Silletti et al. 1993; Honn, Tang et al. 1994; Astudillo, Perez-Chacon et al. 2011; 
Astudillo, Balgoma et al. 2012). 
1.3 Platelet- type 12-Lipoxygenase  
 
12-Lipoxygenase is a cytosolic enzyme.  This enzyme is present in higher 
amounts in platelets, but is also present in smooth muscle cells (Kim, Gu et al. 
1995), keratinocytes (Krieg, Kinzig et al. 1995), and endothelial cells.  12-LOX is 
regulated by alterations in cellular oxidation and reduction conditions that are 
dependant on relative concentrations of reduced cytosolic glutathione and lipid 
hydroperoxidase (Shornick and Holtzman 1993; Kuhn and Thiele 1999).  The 
enzymatic activity of 12-LOX is influenced by extracellular growth factors, cellular 
differentiation state, and sub-cellular compartmentalization (Tang and Honn 
1999).  Recently our group has demonstrated that there is positive feedback on 
12-LOX expression and that 12-LOX activity is regulated by Src phosphorylation 
(Guo, Zhang et al. 2011) and Dilly A.K et al. to be submitted).  12-LOX 
localization is triggered  by EGF (Chang, Liu et al. 1993; Hagmann, Gao et al. 
1996), phorbal ester (Izumi, Hoshiko et al. 1990), Ca+2 or thrombin (Baba, 
Sakuma et al. 1989; Hagmann, Gao et al. 1996; Ozeki, Nagamura et al. 1999) 
and  stimulation of β4 (Tang et al., unpublished observation).  12-LOX is pro-
thrombotic when activated.  This pro-thrombotic activity is linked to mobilization 
of calcium (Nyby, Sasaki et al. 1996), regulation of tissue factor activation, and 
generation of thrombin in the platelet (Thomas, Morgan et al. 2010). 
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1.4 Expression of 12-Lipoxygenase in Cancer 
 
Different LOX isoforms vary in the individual mechanism and their role in cancer.  
In general 5-LOX and platelet type 12-LOX play a role in carcinoma and are 
considered procarcinogenic,  the role of 15-LOX-1 is unclear and being debated, 
while 15-LOX-2 has a unique role and is known  to suppress carcinogenesis (van 
Leyen, Duvoisin et al. 1998; Shureiqi and Lippman 2001).  LOX expression and 
activity in both normal and cancer epithelial tissues from humans and mice were 
examined.  The result revealed that human 15-LOX-1 and -2, or the 
corresponding mouse orthologs leukocyte 12-LOX and 8-LOX, are usually 
preferentially expressed in normal tissues and benign lesions, but not in 
carcinomas of the bladder, breast, colon, lung or prostate.  In contrast, 5-LOX 
and platelet type 12-LOX are generally not expressed in normal epithelia but can 
be induced by pro-inflammatory stimuli.  Several lines of evidence implicate 12-
LOX as a regulator of human cancer development.  The expression of platelet-
type 12-LOX has been confirmed in various tumor cell lines of different tissue 
origins.  It is over expressed in a variety of tumors including melanoma, breast 
cancer, cervical cancer, ovarian cancer, colorectal cancer, prostate cancer, skin 
cancer,  and pancreatic cancer  (Chang, Liu et al. 1993; Kim, Gu et al. 1995; 
Krieg, Kinzig et al. 1995; Natarajan, Esworthy et al. 1997; Nie, Hillman et al. 
1998; Ding, Kuszynski et al. 1999; Timar, Raso et al. 1999; Aran, Bryant et al. 
2011).  Recently it has been shown that 12-LOX and its metabolite 12(S)-HETE 
are important regulators of ovarian cancer growth (Guo, Liu et al. 2011).  Gao et 
al. in his study involving over 130 prostate cancer patients, found that the 12-
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LOX mRNA expression level is correlated with tumor stage and grade  (Gao, 
Grignon et al. 1995).  The 12-LOX RT-PCR sequence products from human 
epidermoid A431 cancer cells, prostate cancer cultured cell lines as well as 
prostate tissues have complete homology to the platelet-type 12-LOX (Gao, 
Grignon et al. 1995; Hagmann, Gao et al. 1996). The product of 12-LOX activity, 
12(S)-HETE, was identified in tumor cells and its structure was confirmed by 
mass spectrometry (Liu, Marnett et al. 1994).  Just as with prostate cancer, 
elevated levels of 12-LOX were found to be of great prognostic value for TNM 
staging in the case of breast cancer (Jiang, Douglas-Jones et al. 2003; Jiang, 
Douglas-Jones et al. 2006) 
 
1.5 Role of 12-Lipoxygenase and its product 12(S)-HETE in 
Tumor Metastasis 
 
Eicosanoids and other bioactive lipids are known to be involved in various 
aspects of neoplasia including cell transformation, tumor promotion, and tumor 
cell growth, and metastasis (Honn, Tang et al. 1994).  During metastasis tumor 
cells interact with platelets, endothelial cell, and matrix protein undergoing 
various cell-host interactions.  It has been demonstrated that 12-LOX stimulates 
prostate carcinoma tumor growth in vivo.  This effect on tumor growth is closely 
related to increased angiogenesis (Nie, Hillman et al. 1998). The growth and 
metastasis of solid tumors is dependent on the ability of tumor cells to induce 
angiogenesis.  12(S)-HETE, has been shown to protect tumor cells from 
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apoptosis and induce invasion, motility, and angiogenesis (Honn, Tang et al. 
1994; Gao and Honn 1995; Nie, Tang et al. 2000; Nie, Tang et al. 2000), as well 
as surface expression of αvβ3 integrin (Tang, Grossi et al. 1993).  Addition of  
exogenous 12(S)-HETE alters the cancer cell cytoskeleton through 
phosphorylation of cytoskeletal proteins (Tang and Honn 1997),  increases tumor 
cell adhesion and spreading on in vitro matrices (Timar, Chen et al. 1992; Timar, 
Silletti et al. 1993), secretion of proteinases (Honn, Timar et al. 1994; Liu, 
Connolly et al. 1996), expression of integrins (Chopra, Timar et al. 1991; Tang, 
Diglio et al. 1995), and it increases invasion.  Pre-treatment of tumors with 12(S)-
HETE stimulates cell motility (Silletti, Timar et al. 1994) and increases the 
surface expression of αvβ integrins, specifically αvβ3 integrin. (Honn, Tang et al. 
1994).  The adhesion of B16 murine melanoma cells to micro-vascular 
endothelial cells was enhanced via up-regulation of αvβ3 integrin resulting from 
treatment with 12(S)-HETE (Tang, Grossi et al. 1993).  Furthermore, it has been 
demonstrated by Honn et al. in 2003 that 12-LOX regulates cell survival and 
apoptosis by affecting the expression and localization of integrins αvβ3 and αvβ5 
in both PC3 and A431 human cancer cells.  It has been reported in certain 
circumstances that metastasis of tumor cells is enhanced by low dose radiation, 
where 12(S)-HETE biosynthesis leads to induced onset of elevated 12(S)-HETE 
(Onoda, Piechocki et al. 1992; Onoda, Kantak et al. 1994).  Another positive 
correlation between biosynthesis of 12(S)-HETE and the metastatic potential of 
murine B16a cells was observed.  The highly metastatic cells demonstrated a 
five to ten-fold increase in lung colonizing ability, over the low metastatic cell 
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lines, due to elevated levels of 12(S)-HETE and 12-LOX mRNA (Honn, Tang et 
al. 1994).  12(S)-HETE is a crucial intracellular signaling molecule involved in 
activation of various signaling pathways.  It activates PKCα via PLCγ1 and 
stimulates PKCζ via inositide kinase.  It also activates MAPK kinase and 
mediates biological functions of many growth factors such as bFGF, PDGF, EGF 
and AMF (Liu, Khan et al. 1995; Wen, Nadler et al. 1996; Hagerman, Fischer et 
al. 1997; Wen, Scott et al. 1997).  Studies have identified the role of 12-LOX in 
tumor cell metastasis using the selective 12-LOX inhibitor BHPP (now called 
BMD122).  BMD122 was demonstrated to inhibit 12-HETE metabolism while not 
inhibiting production of 15-HETE or other mono-hydroxy fatty acids (Chen, 
Duniec et al. 1994).  BMD122 treatment led to apoptosis of cancer cells, which 
was counteracted by over expression of 12-LOX, or by exogenously added 
12(S)-HETE.  Thus, the role of 12(S)-HETE in these signaling events was 
confirmed by inactivation of endogenous 12(S)-HETE production with a specific 
12-LOX inhibitor 
1.6 Regulation of 12-Lipoxygenase by Extracellular and 
Intracellular Factors 
 
12-LOX activity is regulated by both extracellular and intracellular factors, which 
influence the expression of 12-LOX at the mRNA and protein level.  Extracellular 
factors like EGF, AMF, PDGF, TPA, TGF-α , IL-3, 4, 8 (Natarajan, Bai et al. 
1996; Heydeck, Thomas et al. 1998; Liaw, Liu et al. 1998; Chen, Chen et al. 
1999; Tang and Honn 1999) and the intracellular factors  like glucose, 
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angiotensin II, serum, fibronectin and glucocorticoids (Natarajan, Gu et al. 1993; 
Kuchinke and Funk 1994; sChang, Kao et al. 1995; Hagmann, Gao et al. 1996) 
are known to regulate 12-LOX activity.  It is also regulated by the oxido-reduction 
changes in the cell that depend on the relative concentration of glutathione and 
lipid hydroperoxides in the cytosol (Shornick and Holtzman 1993).  12-LOX is 
regulated by the positive feedback of 12(S)-HETE, and sub-cellular 
compartmentation (Hagmann and Borgers 1997; Tang and Honn 1999).  In HEL 
cells 12-LOX is suppressed by transcription factors like NF-ĸB which play an 
important role in the control of cell proliferation and apoptosis (Arakawa, 
Nakamura et al. 1995).  In turn it has been shown that either over-expression of 
the platelet-type 12-LOX or exogenously added 12(S)-HETE activates NF-ĸB 
(Kandouz, Nie et al. 2003).  In a study by Chang et al., 12-LOX protein 
expression and activity both were induced by EGF in A431 human epidermoid 
carcinoma cells but the pretreatment of A431 cells with  glucocorticoids  down 
regulated both expression and activity through the glucocorticoid receptor 
(sChang, Kao et al. 1995). 
1.7 Regulation of 12-Lipoxygenase by Subcellular 
Compartmentalization 
 
The distribution of 12-LOX activity varies among different cell lines and does not 
correspond to the distribution of 12-LOX protein.  The 12-LOX activity within a 
cell varies by compartments and can be found both in the cytosolic and 
particulate or membranous fraction.  In human cancer cells such as A431, HEL 
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cells and murine B16a melanoma cells, the 12-LOX activity reported by 12(S)-
HETE production, is mostly localized to the membranous fraction, though the 12-
LOX protein is mainly localized in the cytosol  (Chang, Ning et al. 1992; 
Hagmann, Kagawa et al. 1993; Hagmann, Gao et al. 1996).  In Lewis lung 
carcinoma cells (3LL), 12-LOX activity and protein are both localized in the 
cytosol.  Though 12-LOX gets translocated from the cytosol to the membrane in 
a Ca+2 dependent manner, the enzymatic activity is lost at the membrane 
(Marnett, Leithauser et al. 1991; Hagmann, Gao et al. 1995).  In A431 cells, EGF 
stimulation can promote 12-LOX translocation and activation (Chang, Ning et al. 
1992; Hagmann, Gao et al. 1996), while in HEL cells translocation can be 
stimulated by TPA treatment (Hagmann, Kagawa et al. 1993).  It has been 
observed in HEL, 3LL cells and platelets that there is a dependence of 12-LOX 
on transient elevation of intracellular free calcium for its translocation to the 
membrane (Baba, Sakuma et al. 1989; Hagmann, Kagawa et al. 1993).  Thus 
12-LOX activity is modulated by subcellular distribution and translocation from 
the cytosol to membrane. 
1.8 12-Lipoxygenase Interacting Partners 
 
In order to identify the potential regulators of platelet type 12-lipoxygenase Tang 
et al., performed a yeast two-hybrid screen using full-length human platelet type 
12-LOX as bait (Tang, Finley et al. 2000).  Using this yeast two-hybrid screen 
approach they screened a human epidermoid carcinoma A431 cDNA library for 
12-LOX interacting proteins. Following the screening of 3X106 cDNA clones, four 
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cellular proteins were identified that specifically interact with platelet type 12-LOX 
(Tang, Finley et al. 2000).  Sequence analysis of the 12-LOX interacting proteins 
revealed that one of these encoded the cytoplasmic domain of the human β4 
integrin subunit.  The other three proteins are type-II keratin K5, nuclear 
envelope protein lamin A and C8FW phosphoprotien.  These proteins provide 
first candidate regulators of 12-LOX.  β4 integrin is the only integrin protein with a 
unique long cytoplasmic tail (1004 amino acid) and is a major component of 
hemidesmosomes.  The following chapters discuss why Integrin β4 is so 
important to the interaction between platelet type 12-LOX and integrin β4 subunit. 
1.9 Integrins 
 
Integrins are heterodimeric transmembrane receptors that mediate either 
attachment of cells to extracellular matrix, or direct cell to cell interaction.  They 
have a large extracellular domain, a transmembrane region and a short 
cytoplasmic tail.  In mammals, 18 α subunits combine with 8 β subunits to 
produce a total of 24 integrin molecules with distinct, but often overlapping ligand 
binding abilities. Integrins link the intracellular and extracellular environment by 
transducing signals across the membrane in both directions.  Binding of the 
ligand to the extracellular domains of integrin triggers a variety of signaling 
pathways due to the conformational changes that are transmitted through the 
plasma membrane to their cytoplasmic tails (Clark and Brugge 1995; Schwartz, 
Schaller et al. 1995; Hynes 2002).  At focal adhesions integrins are clustered 
only after they are activated and bound to ligand (Cluzel, Saltel et al. 2005).  In 
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addition to binding ligand and organizing the cytoskeleton, integrins trigger the 
intracellular signaling pathways that control cell survival and proliferation (Hynes 
1992; Giancotti 1997).  Among the super family of integrins, α6β4 is unique and  
characterized by the presence of  a long cytoplasmic tail about 1004 amino acid 
long, which has distinctive cytoskeleton and signaling functions (Giancotti and 
Tarone 2003). 
1.10 Integrin α6β4  
 
The α6β4 integrin is an essential component of hemidesmosomes; junctional 
complexes in the basal layer of stratified epithelia that connect the intermediate 
filament system to the extracellular matrix (ECM) (Lee, Lotz et al. 1992; Spinardi, 
Ren et al. 1993; Niessen, Hogervorst et al. 1994; Borradori and Sonnenberg 
1996; Dowling, Yu et al. 1996).  The distinguishing structural feature of α6β4 is 
the atypical cytoplasmic domain of the β4 subunit.  The large β4 cytoplasmic tail 
is encoded by ∼1000aa, compared to ∼50aa for all other known β integrin 
subunits (Hogervorst, Kuikman et al. 1990; Suzuki and Naitoh 1990).  Sequence 
analysis of the integrin β subunit shows the presence of four regions that are 
homologous to fibronectin type III (FNIII) domains.  The FNIII regions are 
arranged as two pairs of tandems that are separated by a connecting segment 
(Suzuki and Naitoh 1990).  Most of the known functions of the cytoplasmic 
domain reside in the first pair of FNIII domains and the connecting segment 
(FN1:FN2:CS).  In epithelial cells this region (FN1:FN2:CS) is essential for 
mediating incorporation of β4 into the hemidesmosomes (Spinardi, Ren et al. 
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1993).  The second FNIII-like domain of the β4 cytotail and a small region of the 
adjacent CS are known to interact with plectin (Rezniczek, de Pereda et al. 
1998).  Distal regions of the β4  tail have also been implicated in interactions with 
plectin as well as with two other major components of hemidesmosomes, namely 
BPAG1 and BPAG2 (Wilhelmsen, Litjens et al. 2006).  Yeast two-hybrid studies 
have shown that the same region also interacts with p27BBP/eIF6, an elongation 
initiation factor that localizes to hemidesmosomes in epithelial cells expressing 
α6β4 (Biffo, Sanvito et al. 1997; Sanvito, Piatti et al. 1999).  (Figure 1.3 structural 
biology of hemidesmosome;  
 
           
 
Figure 1.3: Structural biology of hemidesmosome 
 
Source: xtal.cicancer.org/.../hemidesmosome_scheme01.jpg) 
The primary function of β4 is to maintain epithelial integrity especially in the 
epidermis (Dowling, Yu et al. 1996; van der Neut, Krimpenfort et al. 1996).  
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Binding of laminin to α6β4 integrin leads to activation of Ras-ERK and Rac-JNK 
mitogen activated protein kinase (MAPK) pathways in keratinocytes (Mainiero, 
Pepe et al. 1995; Mainiero, Murgia et al. 1997). Additionally laminin also 
activates phosphatidylinositol-3 kinase (PI-3K) (Shaw, Rabinovitz et al. 1997).  
Protein-protein interaction of β4 is governed by its phosphorylation state.  
Dephosphorylation of this β4 cytoplasmic tail leads to association with keratin 
cytoskeleton and assembly of hemidesmosomes (Spinardi, Ren et al. 1993; 
Murgia, Blaikie et al. 1998; Dans, Gagnoux-Palacios et al. 2001).  α6β4 cross-
talks with multiple receptor tyrosine kinases (RTK’s).  Activation of EGF receptor 
(EGF-R) and Met leads to increased phosphorylation of β4  and Shc  signaling 
causes disassembly of hemidesmosomes, and leads to increased cell motility 
and  proliferation (Mariotti, Kedeshian et al. 2001; Trusolino, Bertotti et al. 2001). 
This joint regulation of α6β4 and tyrosine kinase signaling promotes epithelial cell 
survival, proliferation and migration (Mainiero, Murgia et al. 1997; Mariotti, 
Kedeshian et al. 2001; Jonkman, Pas et al. 2002; Weaver, Lelievre et al. 2002; 
Iacovacci, Cicuzza et al. 2003).  Deregulation of this system plays an important 
role in carcinoma invasion and growth (Shaw, Rabinovitz et al. 1997; Wen, Scott 
et al. 1997).  In the absence of α6β4 skin retains normal morphology, but the 
epidermis detaches in response to mechanical stress resulting in death shortly 
after birth (DiPersio, van der Neut et al. 2000).  Compound heterozygote for 
premature termination-codon mutations (C738X/4791delCA), and missense 
mutation involving a cysteine residue (C61Y) in α6β4, both causes a lethal type 
of epidermolysis bullosa, a disorder associated with severe skin blistering (Uitto, 
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Pulkkinen et al. 1997; Jonkman, Pas et al. 2002; Iacovacci, Cicuzza et al. 2003).  
In contrast to its function in regulating stable adhesion through hemidesmosome 
formation in epithelial cells, studies have revealed that α6β4 integrin promotes 
motility and invasion in carcinoma cells (Borradori and Sonnenberg 1996).  It is 
also interesting to note that invasion in breast cancer induces β4 integrin 
expression in stromal fibroblasts to protect them from anoikis during tissues 
remodeling (Kim, Gao et al. 2012).  
1.11 β4 Integrin and Cancer 
 
The β4 integrin was initially identified as a tumor specific protein (TSP180) 
unregulated in metastatic variants of mouse lung carcinoma and melanoma cell 
lines (Kennel, Foote et al. 1981; Falcioni, Kennel et al. 1986).  Many studies have 
provided evidence that the expression of β4 increases significantly during 
malignant progression in squamous carcinoma of multiple tissues, including head 
and neck, skin, cervix and lung (Van Waes, Kozarsky et al. 1991; Carico, French 
et al. 1993; Savoia, Trusolino et al. 1993; Boelens, van den Berg et al. 2007).  
High levels of β4 integrin have been linked to poor prognosis in breast cancer 
(Tagliabue, Ghirelli et al. 1998) and bladder cancer (Grossman, Lee et al. 2000), 
and also in tumor cells invading gastric cancer (Tani, Karttunen et al. 1996).  It is 
also interesting to note that invasion in breast cancer induces β4 integrin 
expression in stromal fibroblasts to protect them from anoikis during tissue 
remodeling (Kim, Gao et al. 2012).  High levels of β4 integrin have been detected 
in colorectal, pancreatic and epitheloid pleural malignant mesothelioma (Giancotti 
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2007).  In addition, α6β4 is also expressed in tumor blood vessels thereby 
promoting the invasive phase of tumorogenesis (Falcioni, Kennel et al. 1986).  
Thus, the expression of β4 integrin confers evolutionary advantage during 
tumorigenesis.  Interestingly β4 perform two contrasting roles, stable adhesion, 
and pro-invasive signaling.  It promotes assembly of hemidesmosomes to 
mediate stable adhesion, and restrains cell migration by connecting the keratin 
cytoskeleton to the basement membrane.  The disassembly of hemidesmosomes 
takes place when β4 integrin is relocated from hemidesmosomes to the leading 
edge in migrating keratinocytes.  In carcinoma cells it is enriched at lamellipodia 
causing migration.  This shows that there is a dynamic regulation that allows both 
normal cell migration and carcinoma invasion (Mariotti, Kedeshian et al. 2001; 
Mercurio and Rabinovitz 2001; Litjens, de Pereda et al. 2006).  It has been 
reported earlier that β4 contains multiple tyrosine phosphorylation sites in the 
cytoplasmic domain namely, Y1422, Y1440, Y1494, Y1526, and Y1642.  It 
combines with SRC family kinases (SFK) and also mediates recruitment of 
signaling adapter protein Shc and activation of Ras to stimulate the ERK 
signaling pathway (Mainiero, Pepe et al. 1995; Mainiero, Murgia et al. 1997; 
Dans, Gagnoux-Palacios et al. 2001; Gagnoux-Palacios, Dans et al. 2003).  In 
addition it also activates PI-3K kinase.  Binding of commercial antibody 3E1 
(Chemicon Inc.) or laminin to β4 activates Ras and PI-3K signaling (Mainiero, 
Pepe et al. 1996; Mainiero, Murgia et al. 1997; Shaw, Rabinovitz et al. 1997).  
Assembly of hemidesmosomes is prevented by both SFK mediated tyrosine 
phosphorylation and PKC-mediated serine phosphorylation of the β4 cytoplasmic 
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tail (Dans, Gagnoux-Palacios et al. 2001; Rabinovitz, Tsomo et al. 2004).  β4 
integrin ligation is sufficient to promote cell migration but RTK activation is 
necessary for cell proliferation and sustained migration (Giancotti and Tarone 
2003; Giancotti 2007).  β4 combines with numerous RTKs including EGF-R, 
ErbB2, Met and Ron (Mariotti, Kedeshian et al. 2001; Trusolino, Bertotti et al. 
2001; Santoro, Gaudino et al. 2003; Guo, Pylayeva et al. 2006).  RTKs induce 
activation of SFKs on stimulation of β4,   and leading to phosphorylation of the β4 
cytoplasmic tail (Mariotti, Kedeshian et al. 2001; Santoro, Gaudino et al. 2003; 
Giancotti 2007).  Additionally, while ERK and Akt are efficiently activated by 
mitogeic concentrations of EGF they fail to induce nuclear translocation of ERK, 
JNK and NF-kB when plated on lamimin-5.  Therefore β4 signaling also controls 
nuclear translocation of many transcription factors (Nikolopoulos, Blaikie et al. 
2004; Nikolopoulos, Blaikie et al. 2005).   β4 combine with EGF-R, ErbB-2 and 
Met RTKs, which are often mutated or amplified during tumor progression.  This 
suggests that dysregulated joint β4- RTK signaling contributes to carcinoma 
invasion and growth (Giancotti 2007).  This is supported by the observation that 
expression of wild type β4 in β4-negative breast carcinoma cells that express the 
HGF receptor Met, activates signaling from PI-3K to Rac and enhances their 
invasive properties (Shaw, Rabinovitz et al. 1997) whereas dominant negative 
inhibition of β4 impairs survival and adhesion of breast carcinoma cells (Weaver, 
Lelievre et al. 2002) .  Further, over expression of β4 promotes ErbB-2 
dependent cell invasion and proliferation in cancer cells (Falcioni, Kennel et al. 
1986).  Tyrosine phosphorylation of β4 also occurs through Fyn, as inhibition of 
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Fyn suppresses tyrosine phosphorylation of β4 thereby leading to 
hemidesmosome reassembly and reduced invasion of squamous carcinoma cells 
expressing elevated levels of EGF-R (Mariotti, Kedeshian et al. 2001; Giancotti 
2007).  The β4 tail functions as an adapter and amplifier for pro-invasive signals 
elicited by Met in cells that undergo Met-mediated oncogenesis (Trusolino, 
Bertotti et al. 2001).  Likewise, binding of Shp2 to β4 integrin enhances activation 
of the Src signaling pathway, which is required for further induction of anchorage 
independent growth,  mediated by β4 in breast carcinoma cells (Bertotti, 
Comoglio et al. 2006).  Collectively these studies suggest that unliganded β4 
amplifies signaling by oncogenic RTKs (Giancotti 2007), while on other hand, 
liganded β4 is required for Ras-mediated transformation in keratinocytes, thus 
promoting cell survival and proliferation (Dajee, Lazarov et al. 2003).  β4-
mediated assembly of hemidesmosome leads to cell growth and polarity in 
normal cells however β4 signaling promotes cell proliferation and invasion in 
cancer cells.  Thus β4 integrin plays a very important role as a signaling hub in 
cell proliferation, apoptosis, differentiation, adhesion, invasion and metastasis.   
 
1.12 Interaction between P-12-LOX and β4 Integrin Subunit 
 
Initial studies by Tang have shown by yeast two-hybrid screening the binding 
partners of P-12-LOX using full length human P-12-LOX as bait to screen a 
human epidermoid carcinoma A431 cell line cDNA library (Tang, Finley et al. 
2000).  Following the screening of 3X106 cDNA clones, four cellular proteins 
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were found to interact specifically with 12-LOX.  Sequence analysis identified one 
of them as cytoplasmic domain of human β4 integrin subunit (Tang, Finley et al. 
2000).  The uniqueness of β4 integrin and its important role in cell proliferation, 
apoptosis, differentiation, adhesion, invasion and metastasis have been already 
discussed.  Therefore, the main focus of this project was on the interaction of P-
12-LOX and the β4 subunit both physically and for functional relevance (Tang et 
al., unpublished observation).  The study confirms that P-12-LOX physically 
interacts with the cytoplasmic domain of β4 by yeast two-hybrid screening but 
also by co-immunoprecipitation from the mammalian cells and co-localization by 
confocal microscopy.  Tang reported that stimulation of A431 cells with the anti-
β4 mAb 3E1 increased P-12-LOX association with β4, and found that the 
extracellular domain of the β4 subunit appears to serve as a receptor for 
extracellular stimuli which triggers a signaling mechanism that plays a role in the 
interaction of the cytoplasmic tail with 12-LOX (Tang et al., unpublished 
observation).  Confocal microscopic analyses of the two proteins revealed that 
12-LOX is primarily localized in the cytosol and upon stimulation of β4 integrin 
becomes co-localized at the membrane.  The data suggested that β4 subunit 
mediates the translocation of 12-LOX from the cytoplasm to the membrane and 
provided the first regulatory protein that impacts 12-LOX localization.  The co-
immunoprecipitation data and confocal microscopy data provide significant 
evidence for a physical association between 12-LOX and the cytoplasmic domain 
of β4.  This association between 12-LOX and the cytoplasmic domain of β4 after 
integrin ligation promotes cell migration in response to EGF as a chemo-
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attractant.  Additionally, the functional relevance of this association for enzymatic 
activity was demonstrated by the RP-HPLC and EIA data where 12(S)-HETE 
biosynthesis was increased following cell stimulation with β4 mAb 3E1.  The 
physical interaction of P-12-LOX with β4 integrin subunit up-regulates its 
enzymatic activity which is measured by 12(S)-HETE production.  It also protects 
cells from apoptosis induced by the 12-LOX inhibitor, BMD122, suggesting a 
relationship between β4 ligation, enhanced 12-LOX activity, and protection from 
apoptosis.  Also the migration data suggest that 12-LOX activity is important for 
EGF-stimulated, α6β4-dependent, cell migration upon treatment with 3E1 mAb 
antibody or laminin.  Tang et al.  demonstrated that 12-LOX interacts with the 
integrin β4 both physically and functionally, thus providing  insight for both 
integrin and eicosanoid biology (Tang, Finley et al. 2000).  The known correlation 
between 12-LOX and tumor progression and metastasis, and the insight from this 
study reveals another facet of the complicated role of the integrin α6β4 in cancer 
and other human diseases and may provide a new target for therapy and 
treatment.  The focus of this study was to establish which residues or motifs in 
the cytoplasmic domain of β4 are critical for 12-LOX binding and to associate 
these with phenotypes that are functionally relevant to cancer progression.  
Future studies will determine what reciprocal sites of the 12-LOX protein are 
responsible for the interaction with β4. 
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1.13.1 Results and Discussion  
 
1.13.1.1 12-LOX-β4 interaction is selectively specific and β4 
stimulating antibody 3E1 has the same effect as its 
natural ligand laminin 
We have previously identified the potential regulators of 12-LOX by the yeast 
two-hybrid screen of an A431 library and found that 12-LOX interacts with the C-
terminal cytoplasmic domain of the integrin β4 subunit (Tang, Finley et al. 2000). 
In this study we confirmed endogenous interaction of 12-LOX with β4 using the 
A431 cell line by performing a co-immunoprecipitation assay.  We performed 
immunoprecitation on 3E1 or laminin-stimulated A431 cells with anti 12-LOX and 
probed with β4 and found 12-LOX co-immunoprecipitated with β4.  Regardless of 
stimulus, the association of 12-LOX with β4 was time-dependent and began at 5 
minutes post stimulation, peaked at 60 minutes, and declined at 90 minutes 
(Figure 1.4).   This was suggestive of a specific association between 12-LOX and 
β4.  These data suggests that the interaction between 12-LOX and β4 is specific 
and that a β4 stimulating antibody elicits the same response as laminin with 
respect to 12(S) - HETE production and associated phenotypes.   
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1.13.1.2 The β4 and 12-LOX interaction increases 12-LOX 
enzymatic activity 
The enzymatic activity of 12-LOX, followed by β4 integrin stimulation was 
determined by LC-MS analysis, for its sole AA metabolite 12(S)-HETE.  Lipid 
extraction was performed as described in Materials and Methods.  CHO stable 
transfectant cells were stimulated either with β4 stimulating antibody (3E1), or its 
natural ligand (laminin) followed by incubation with 10 μM AA for 6 hours.   The 
results revealed that 12-LOX activity was increased when 12-LOX interacts with 
β4 integrin and was further enhanced on stimulation (Figure 1.5).  Taken 
together, we conclude that the interaction of 12-LOX with the β4 subunit up-
regulates 12-LOX enzymatic activity. 
1.13.1.3 12-LOX plays a role in EGF-stimulated cell migration 
 
 
It has been previously shown that EGF enhances α6β4-dependent cell migration 
of A431 cells on laminin (Mainiero, Pepe et al. 1996; Rabinovitz, Toker et al. 
1999).  As 12-LOX interacts physically and functionally with β4 in A431 cells, we 
tested whether 12-LOX modulates α6β4 -dependent migration upon stimulation 
with laminin or β4 antibody 3E1.   We demonstrated that EGF induced A431 cell 
migration by 2-2.5 fold.  Interestingly  pretreatment of cells with 12-LOX specific 
inhibitor BMD122 inhibits 12-LOX and  reduces A431 cell migration to the level 
observed in the absence of EGF stimulation (Figure 1.6), which is in agreement 
with  previous reports (Rabinovitz, Toker et al. 1999).   Laminin and 3E1 antibody 
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induced migration through matrigel equally well.  However, migration was 
inhibited to a greater degree in laminin treated cells.  Our data suggest that 12-
lipoxygenase activity is important for EGF-stimulated, α6β4-dependent, cell 
migration upon stimulation with laminin or 3E1.  
1.13.1.4 Intracellular Co-localization of 12-LOX and β4 Integrin 
 
 
The physical association between 12-LOX and the β4 subunit was confirmed by 
assessing intracellular co-localization by double labeling and examination by 
confocal microscopy.  Sub-confluent A431 cells were serum starved overnight 
and treated with 5 μg/ml laminin for two hours and β4 antibody 3E1, or non-
specific mouse IgG for one hour.  Cells were labeled simultaneously with P-12 
LOX antibody and β4 antibody followed by the labeling with the respective 
secondary antibodies Alexa488 (green) and Alexa594 (red) (Figure 1.7).  
Overlapping areas of staining appear yellow in confocal images in the cells 
stimulated with laminin and 3E1, indicating 12-LOX-β4 colocalization (Fig. 1.7 A 
and B).   The unstimulated cells or the cells treated with mouse IgG, showed no 
co-localization (Fig. 1.7 C and D).  Controls were stained with secondary 
antibody alone and showed no cross reactivity with the background (Fig. 1.7 E).   
These data show 12-LOX-β4 co-localization which supports the biochemical 
evidence that 12-LOX physically interacts with β4. 
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1.13.2 Summary 
 
In summary, we have demonstrated that 12-LOX interacts with the cytoplasmic 
domain of the β4 subunit in mammalian cells.  12-LOX colocalizes with β4 at the 
edge of the cell membrane and some peri-nuclear staining was also observed.   
12-LOX-β4 interaction results in an increase in 12-LOX enzymatic activity that is 
further enhanced upon stimulation with 3E1 or laminin, and culminates in 
increased cell migration.  These data represents the novel interaction between 
12-LOX and integrin β4, both physically and functionally, thus providing a new 
paradigm for both integrin and eicosanoid biology.  Given the demonstrated 
correlation between 12-LOX expression and tumor progression and metastasis, 
results from this study reveal a complicated role of the integrin α6β4 in cancer 
and other human diseases and may provide new potential therapeutic targets.  
Studies presented in this dissertation established which residues or motifs in the 
cytoplasmic domain of β4 are critical for 12-LOX binding  
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Figure 1.4:  P-12-LOX interacts with integrin β4 subunit in vitro.  A431 cells were 
stimulated with mAb β4 3E1 or laminin and harvested at timed intervals from 5-
90 minutes.  12-LOX and the β4 subunit were co-immunoprecipitated from 
untransfected A431 cells (A431).  β4 subunit was detected with mAb 450-11A. 
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Figure 1.5: LC-MS analysis of 12-LOX products to determine 12-LOX activity.  
CHO transfectant cells were stimulated with mAb β4 or laminin for 30 minutes 
followed by treatment with 10 μM AA for 6 hour.   Cell lipids were extracted and 
analyzed as described in Materials and Methods.  The data show increased 
12(S)-HETE production in cells co-transfected with 12-LOX and β4 that is 
enhanced when stimulated with laminin or 3E1.  The data shown are the mean 
value (±SEM) from three experiments as represented in (A), error bars indicate 
SEM.  Data is significant since p < 0.05 from student t test. 
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Figure 1.6: The α6β4 integrin and 12-LOX activity function in EGF-induced cell 
migration.  (A) Comparison of cell migration of A431 cells in the presence of EGF 
chemoattractant when cells stimulated with either mAb 3E1 or laminin in the 
presence or absence of the 12-LOX specific inhibitor BMD122.   (10X magnification).  
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(B) A431 cells were pretreated with 3E1 antibody for 20 minutes, or laminin with or 
without EGF (1 ng/ml) for 3 hours in the presence or absence of pharmacological 
inhibitors as described in Materials and Methods.  Data represent the mean number 
of transmigrated cells/microscopic field (± SE).   
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Figure 1.7 
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Figure 1.7: 12-LOX co-localizes with β4 by laser confocal immunofluorescence 
microscopy. A431 cells were treated, fixed, permeabilized, and sequentially incubated 
with primary antibodies 12-LOX (green) Oxford pAb and/or mouse anti-β4 (red) mAb 
3E1 antibodies.  Conjugated secondary antibodies Alexa488 (green) or Alexa594 (red) 
were used for detection: Yellow color indicates colocalization of 12-LOX (green) and 
integrin subunit β4 (red); (A) Laminin stimulated cells (B) 3E1 stimulated cells, (C) 
Unstimulated cells (D) & (E) Both secondary antibodies controls.  A’, B’, C’, D’, and E’ 
are magnified regions of interest. 
 
 
 
E 
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1.14 Statement and Hypothesis 
 
 A yeast two-hybrid screen approach was used to identify the potential, direct 
regulators of 12-LOX.  The study revealed four interacting partners including the 
cytoplasmic domain of the human β4 integrin subunit (Tang, Finley et al. 2000).  
This putative interaction was confirmed by P-12-LOX co-immunoprecipitation 
with the cytoplasmic domain of β4, and co-localization with β4 integrin as 
observed by confocal laser microscopy in mammalian cells (Tang et al., 
unpublished observation).  β4 integrin upon stimulation with its natural ligand 
laminin, or β4-activating 3E1 (mAb), induced 12-LOX translocation from the 
cytosol to membrane.  This provided the first candidate protein that may directly 
mediate 12-LOX translocation.  Additionally, the association of 12-LOX with the 
β4 subunit up-regulates 12-LOX activity as demonstrated in the RP-HPLC and 
EIA data where 12(S)-HETE biosynthesis was increased following cell 
stimulation with β4 mAb 3E1.  The increase in enzymatic activity was due to 
increased interaction of 12-LOX with the cytoplasmic domain of β4.  The results 
demonstrated that the ligation of β4 increased resistance of A431 cells to 
apoptosis induced by BMD122, suggesting a relationship between β4 ligation, 
enhanced 12-LOX activity, and protection from apoptosis. 
 This association also promotes migration in the presence of EGF as a chemo-
attractant, which is decreased in the presence of 12-LOX inhibitor.  Thus it was 
demonstrated for the first time that 12-LOX interacts with the integrin β4 both 
physically and functionally, thereby providing a new insight for both integrin and 
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eicosanoid biology (Tang et al., unpublished observation).  However, it remained 
to be established which residues or motifs in the cytoplasmic domain of β4 were 
critical for 12-LOX binding, and conversely, which domains or motifs of the 12-
LOX protein are responsible for interaction with β4.  In this study we describe for 
the first time the interaction domain of β4 integrin for 12-LOX.  Determination of 
the structural basis for protein-protein interaction may provide a target for 
pharmaceutical intervention.  This physical interaction has functional implications 
with regard to cell survival, cell migration and proliferation, and tumor growth.  
Blocking the 12-LOX β4 interaction will directly interfere with 12-LOX mediated 
signaling originating from β4 integrin or other proteins that function through this 
axis. 
 
1.15.1   Aims 
 
 Determine the structural basis for the interaction between β4 integrin 
subunit and 12-LOX. 
 Determine how β4 regulates 12-LOX cellular localization and activity. 
 Determine the functional implications with regard to cell survival, cell 
migration, proliferation, and tumor growth.  
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1.15.2   Hypothesis 
 
Does interference with the point of interaction between the β4 integrin subunit 
and 12-LOX have functional consequences by reducing tumor cell survival, 
invasion and metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8:  Do 12-LOX and β4 integrin collaborate to regulate cell survival/ 
apoptosis, migration, proliferation, and tumor progression in carcinoma? 
α6 β4
12 LOX
Tumor growth?
12-LOX Activity ?
Cell proliferation ?
Cell migration/Invasion ?
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?
39 
 
 
CHAPTER 2 : Materials and Methods  
 
2.1 Antibodies and Reagents:  
 
Polyclonal antibody 12-LOX that specifically recognize platelet type was obtained 
from Oxford Biomedical Research, (Oxford MI).   Anti-12-LOX 7225, clone 25.20 
and 7261, clone 61.39 mAbs were obtained from American Diagnostica, Inc., 
(Stanford CT).  A mAb specific for the extracellular domain of human β4 integrin 
subunit, clone 3E1, and an anti-human β1 pAb 1952 specific to the C-terminal 
cytoplasmic domain were obtained from Chemicon International, (Billerica, MA).   
The anti- human β4 integrin mAb (clone 450-11A), specific to the cytoplasmic 
domain, was obtained from BD Pharmingen, (San Diego, CA).  The actin 
antibody was from Affinity BioReagents, (Golden, CO).   Myc mAb was 
purchased from Millipore, (Billerica, MA).   Horseradish peroxidase-conjugated 
secondary anti-IgG (mouse and rabbit) were purchased from GE Healthcare, 
(Piscataway, NJ).   Internal standard 12(S)-HETE d8 and arachidonic acid were 
from Cayman Chemical Research Products, (Ann Arbor, MI).   Human laminin, 
EGF and proteosome inhibitor MG132 were purchased from Sigma Aldrich, (St. 
Louis, MO).  BHPP (Biomide compound BMD122), was a generous gift from 
Biomide Corp, (Grosse Pointe Farms, MI), and Baicalein was purchased from 
Calbiochem, (San Diego, CA).  
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2.2 Primers:  
 
A 
 
           
 
 
 
  
 B 
 
 
 
 
β4 FN1 and FN2 sequences (1126-1318) 
FN1 
S  Q  P  P  P  H  G  D  L  G  A  P  Q  N  P  N  A  K  A  A   
G  S  R  K  I  H  F  N  W  L  P  P  S  G  K  P  M  G  Y  R  
V  K  Y  W  I  Q  G  D  S  E  S  E  A  H  L  L  D  S  K  V  
P  S  V  E  L  T  N  L  Y  P  Y  C  D  Y  E  M  K  V  C  A  
Y  G  A  Q  G  E  G  P  Y  S  S  L  V  S  C  R  T  H  Q  E  
 
FN2 
 
V  P  S  E  P  G  R  L  A  F  N  V  V  S  S  T  V  T  Q  L   
S  W  A  E  P  A  E  T  N  G  E  I  T  A  Y  E  V  C  Y  G  
L  V  N  D  D  N  R  P  I  G  P  M  K  K  V  L  V  D  N  P  
K  N  R  M  L  L  I  E  N  L  R  E  S  Q  P  Y  R  Y  T  V  
K  A  R  N  G  A  G  W  G  P  E  R  E  A  I  I  N  L  A  T 
 
Figure 2.1: Schematic design of areas deleted by primers 
 
1126-1318
EC TM IC FN1 FN2 L FN3 FN4 C
EC TM IC FN2 L FN3 FN4 C
Myc
EC TM IC FN1 L FN3 FN4 C
Myc
FN1 deletion (∆FN1)
FN2 deletion (∆FN2)
1126-1221
EC TM IC FN1 FN2 L FN3 FN4 C
EC TM IC FN01 FN02 FN03 FN2 L FN3 FN4 C
FN01-1 FN01-2 FN01-3
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Primer 
Name 
Primer 
FN1 (+) 5'-CAGCCACCCCCTCACGGCGAACAAAAACTTATCAGTGAAGAA 
GATCTGCACCAG GAAGTGCCCAGC -3' 
FN1 (-) 5'-GCTGGGCACTTCCTGGTGCAGATCTTCTTCACTGATAAGTTTTT 
GTTCGCCGTGAGGGGGTGGCTG -3' 
FN2 (+) 5'- CGCACCCACCAGGAAGTGGAACAAAAACTTATCAGTGAAGA 
AGATCTGCAGCCCAAGAGGCCCATG -3' 
FN2 (-) 5'- CATGGGCCTCTTGGGCTGCAGATCTTCTTCACTGATAAGTTT 
TTGTTCCACTTCCTGGTGGGTGCG -3' 
FN01 (+) 5'-CAGCCACCCCCTCACGGCGAACAAAAACTTATCAGTGAAGAA 
GATCTGAGGGTAAAGTACTGGATT -3' 
FN01 (-) 5'- AATCCAGTACTTTACCCTCAGATCTTCTTCACTGATAAGTTTTT 
GTTCGCCGTGAGGGGGTGGCTG -3' 
FN02 (+) 5'- GGCAAGCCAATGGGGTACGAACAAAAACTTATCAGTGAAGAA 
GATCTGTGCGACTATGAGATGAAG -3' 
FN02 (-) 5'- CTTCATCTCATAGTCGCACAGATCTTCTTCACTGATAAGTTTTT 
GTTCGTACCCCATTGGCTTGCC -3' 
FN03 (+) 5'- ACCAACCTGTACCCGTATGAACAAAAACTTATCAGTGAAGAAG 
ATCTGGAGCCAGGGCGTCTGGCC -3' 
FN03 (-) 5'- GGCCAGACGCCCTGGCTCCAGATCTTCTTCACTGATAAGTTTTT 
GTTCATACGGGTACAGGTTGGT -3' 
FN01-1(+) 5'- CAG CCA CCC CCT CAC GGC GCC GCT GGG TCC AGG AAG -3' 
FN01-1(-) 5'- CTT CCT GGA CCC AGC GGC GCC GTG AGG GGG TGG CTG -3' 
FN01-2(+) 5'- CAG AAC CCC AAT GCT AAG CTG CCC CCT TCT GGC AAG -3' 
FN01-2(-) 5'- CTT GCC AGA AGG GGG CAG CTT AGC ATT GGG GTT CTG -3' 
FN01-3(+) 5'- AAG ATC CAT TTC AAC TGG AGG GTA AAG TAC TGG ATT -3' 
FN01-3(-) 5'- AAT CCA GTA CTT TAC CCT CCA GTT GAA ATG GAT CTT -3' 
 
Table 2-1 List of primers used to generate β4 deletion mutants of FN1 and FN2, 
the three sub-domains of FN1 and finally the three micro-domains of FN01, 
namely FN01-1, FN01-2 and FN01-3. 
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2.3 Cell Culture:  
 
Cell lines A431 (human epithelial carcinoma) and CHO (Chinese hamster ovary) 
were obtained from ATCC, (Manassas, VA) and grown in RPMI containing 10% 
FBS.  CHO cells were transfected with 12-LOX in combination with either β4 full-
length or β4 deletion mutants using lipid-based Mirus, (Mirus Bio; Madison, WI).  
A431 cells were transfected with β4 mutants using Geneporter, (AMS 
Biotechnology Ltd.; Lake Forest, CA) and also lipofectamine LTX (Invitrogen Inc.; 
Carlsbad, CA).  For treatment with β4-stimulating antibody 3E1, A431 cells were 
grown to 90% confluence in 100 mm petri dishes and serum-starved overnight 
prior to experimental use.  Cells were then washed with PBS (3x) and incubated 
with β4 stimulating antibody for 30 minutes at a concentration of 5 μg/ml in 
serum-free RPMI medium.  Cells were harvested at defined time intervals for 
further examination. 
 
2.4 Co-immunoprecipitation:  
 
 Cells were washed with 1X PBS (3x)  and placed in cold lysis buffer (1% Triton 
X-100; 150 mM NaCl; 10 mM Tris, pH 7.4; 1 mM EDTA; 1 mM EGTA, pH8.0; 0.2 
mM sodium ortho-vanadate; 0.2 mM PMSF; 0.01% aprotinin; 5 μg/ml leupeptin; 
0.5% NP-40).  The cell lysate was sonicated and clarified by centrifugation 
(10,000 x g; 10 minutes).  Supernatants were pre-cleared with 40 μl Sepharose 
4B conjugated protein G beads at 4°C for 1 hour followed by immunoprecipitation 
with 4 μl of antibody (1 μg/μl) to human P-12-LOX or the β4 integrin subunit 4°C 
for 3 hours with rotation.  Immunoprecipitate was pulled down with 40 μl 
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Sepharose 4B conjugated protein G beads at 4°C overnight with rotation.  
Immune-complexes were washed with PBS buffer (3x), and beads were 
resuspended in SDS sample buffer (85 mM Tris-HCL, pH6.8 containing 1.4 (w/v) 
glycerol, 5% (v/v) mercaptoethanol, and a trace of bromophenol blue), boiled for 
5 minutes, and subjected to SDS-PAGE on  10% or 15% acrylamide gel.  Gels 
were run at 4°C at 130V.  Proteins were electrophoretically transferred to 
nitrocellulose membranes at 4°C for 1 hour and 15 minutes at constant 0.4A.  
After transfer, nonspecific sites were blocked with 5% (w/v) nonfat-dry milk in 
TBST (0.1% Tween-20; 20 mM Tris base; 137 mM NaCl; 3.8 mM HCl, pH 7.6) for 
1 hour at 25°C followed by primary antibody overnight at 4°C.  After washing the 
blot in TBST (3X), the membranes were incubated (1 hour; 25°C) with 
horseradish peroxidase-conjugated secondary anti-IgG (dilution: 1:4500, GE 
Healthcare, Piscataway, NJ).  The blot was washed again in TBS-T, and 
developed using ECL according to the manufacturer's instruction (GE 
Healthcare, Piscataway, NJ). 
2.5 Western Blotting:   
 
Immune complexes or aliquots of total cell lysates were mixed with 1 volume of 
SDS sample buffer (85 mM Tris-HCL, pH6.8 containing 1.4 (w/v) glycerol, 5% 
(v/v) mercaptoethanol, and a trace of bromophenol blue).  Whole cell lysates in 
SDS sample buffer, boiled for 5 minutes, and loaded at 30-60 μg of protein, and 
separated by SDS-PAGE on a 10% or 15% acrylamide gel.  The gels were run at 
4°C at 130V and electrophoretically transferred to nitrocellulose membranes at 
4°C for 1 hour and 15 minutes with constant 0.4A.  After transfer, nonspecific 
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sites were blocked with 5% (w/v) nonfat-dry milk in TBST (0.1% Tween-20; 20 
mM Tris base; 137 mM NaCl; 3.8 mM HCl, pH 7.6) for 1 hour at 25°C followed by 
primary antibody overnight at 4°C.  After washing the blot in TBST (3X), the 
membranes were incubated (1 hour; 25°C) with horseradish peroxidase-
conjugated secondary anti-IgG (dilution: 1:4500, GE Healthcare, Piscataway, 
NJ).  The blot was washed again in TBS-T, and developed using ECL according 
to the manufacturer's instruction (GE Healthcare, Piscataway, NJ). 
2.6 12-LOX Activity Measurement:  
 
 
LC-MS was used to determine the enzymatic activity of 12-LOX by measuring 
12(S)-HETE production in relation to an internal standard.  Transiently 
transfected CHO cells or A431 stable cell lines expressing the GR16 β4 fragment 
or empty vector were serum-starved overnight.  Prior to serum starvation 
‘conditioned’ medium was harvested directly as a control.  Subsequently, cells 
were treated with laminin or the β4-stimulating antibody 3E1 for 1 hour followed 
by a 6 hour treatment with 10 μM AA.  When used, inhibitors such as BMD122 
were given prior to stimulation with 3E1 antibody.  Treatment with 10 μM 
BMD122 was performed for 2 hours in serum-free medium. After treatment the 
media was collected and centrifuged, and the resulting supernatants (cell lipids) 
were extracted.  An internal standard, 10 ng of 12(S)-HETE-d8, was added to the 
samples and then applied to ODS-silica cartridges.  Solid phase extraction for 
mass spectrometry determination of 12-(S) HETE was performed as previously 
described by Suzuki et al (Suzuki, Hishinuma et al. 2003).  The samples were 
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passed through the mobilized columns (methanol treated) and eluted from the 
cartridges with Hexane: ethyl-acetate solution (1:3).  Solvent was evaporated 
under a stream of nitrogen gas and lipids were reconstituted in methanol.  Prior 
to LC-MS analysis, 50 mM of ammonium acetate before was added to each 
sample.  Data shown are significant where p< 0.05 by student’s t test. 
2.7 Expression Constructs and Transfection:   
  
A panel of bacterial expression plasmids that yield recombinant protein in E.coli 
and mammalian expression constructs that express various mutant forms of the 
β4 cytoplasmic tails were generously provided by Dr. Gerhard Wiche (Rezniczek, 
de Pereda et al. 1998).  Stable cell lines were generated that express the β4 
variants as fusion proteins with a GFP reporter.  Expression constructs encoding 
wild-type and truncated human β4 subunits in the pRC-CMV vector were 
generous gifts from Dr. Filippo Giancotti (Giancotti, Stepp et al. 1992).  Briefly, 
the pRC-CMV vector contains either the full length β4 subunit cDNA, β4 Δ FN1 
(aa 1126-1215), or β4 Δ FN2 (aa 1220-1318).   Additional constructs with macro 
deletions, pCMV-β4 Δ FN01 (aa 1126-1157), pCMV-β4 Δ FN02 (aa 1158-1189), 
and pCMV-β4 ΔFN03 (1190-1221), are reported in Table-2.1.  These constructs 
were Myc tagged so as to differentiate them from full length β4, and detected 
using anti- Myc antibody.  Though the deletion mutants could also be detected 
using anti- β4 mAb, the Myc tag was opted for making stable A431 transfectants.  
A431 cells contain endogenous full length β4 and transfecting them with the β4 
fragments with Myc tag makes it easier to differentiate them from full length β4.  
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Thus, Myc tag was used to design all of the β4 deletion mutants.  Fine mapping 
was done by making micro deletions within this FN01 macro domain; pCMV-β4 Δ 
FN01-1 (aa 1126-1136), pCMV-β4 Δ FN01-2 (aa 1137-1147), and pCMV-β4 
ΔFN01-3 (aa 1148-1157).  The full length cDNA encoding human P-12-LOX 
(pCMV-P-12-LOX) was provided by Dr. Colin D. Funk (Queen's University, 
Kingston Ontario, CA).  This cDNA was subsequently subcloned into the EcoRI/ 
XbaI sites of pcDNA3.1 (Invitrogen).  Stable A431 transfectants were generated 
expressing Myc tagged β4 fragment constructs pRC-CMV-GR16 (200 aa) and 
pRC-CMV-FN01-02 (10 aa).  Ampicillin was used for selection of all bacterial 
expression vectors (50 µg /ml).  Transfectants were selected with 350 µg/ ml 
G418 (Sigma Aldrich; St. Louis, MO). 
2.8 Immunofluorescence: 
 
 
A431 cells were grown to 90% confluency on glass cover slips and serum-
starved overnight followed by stimulation with either 5 μg/ml laminin (Sigma 
Aldrich) for 2 hour, or 5 μg/ml mAb 3E1 to β4 integrin (Chemicon) for 1 hour.  
Cover slips  were washed with PBS (3x) and fixed with 3.7% formaldehyde in 
PBS for 5 minutes at 37oC, followed by ice cold methanol fixation for 3 minutes.  
Cells were then permeabilized in an antibody dilution buffer (ADB: Tris-buffered 
saline pH 7.4 containing 0.1% Triton X-100 and 2% BSA) for 10 minutes.   
Primary (1:100) and secondary antibodies (1:500) were diluted in ABD.  Cells 
were incubated first with primary antibody (rabbit anti-human 12-LOX Ab) for 1 
hour at room temperature (RT), followed by (3x) PBS washes.  Later they were 
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incubated for 30 minutes with secondary fluorescent antibody (Alexa488-
conjugated goat anti-rabbit antibody) and washed with PBS (3x).  Further they 
were incubated with mouse anti-human β4 integrin antibody for 1 hour at RT with 
subsequent 3x PBS washes, and 30 minutes Alexa594-conjugated goat anti-
mouse antibody followed by (3x) PBS washes.  Nuclei were visualized by 
incubating for 10 minutes at RT with DAPI (4', 6-diamidino-2-phenylindole) 
followed by (3X) washes.  Cover slips were mounted in Mowiol with 0.5% 
phenylenediamine (anti-fade reagent).  
(http://www3.niaid.nih.gov/labs/aboutlabs/rtb/biologicalImaging/protocols/). The 
slides were observed with a Leica TCS SP5 laser scanning confocal microscope. 
2.9 Cell Invasion and Migration Assay:  
 
 
 Cell migration and invasion assays were carried out in modified Boyden 
chambers using 24 well cell culture plates fitted with 8-um transwell inserts (BD 
Falcon).  The insert membranes were coated with 100 μl of 250 μg/ml Matrigel, 
(BD Pharmingen) for 2 hour at 37°C.  Stable transfectants expressing β4 mutants 
or harboring an empty vector were trypsinized and washed using serum free 
medium, and 5x105 cells were added to the inserts.  When used, inhibitor 
BMD122 (25 μM) was added prior to 3E1 stimulation for 1 hour.  Cells were 
treated with 3E1 antibody (3 μg) for 1 hour.  Medium containing 0.3% serum was 
added to the lower chamber.  Following 24 hours, cells that migrated to the other 
side of the membrane were stained using the “Diff Quick” staining kit (IMEB Inc., 
San Marcos, CA) and photographed.  Quantitative analysis was performed by 
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dissolving the cells and membrane in 10% acetic acid and measuring the 
absorbance at 570nm.  Data are taken as significant where p< 0.05 by student t 
test. 
2.10 Cell Proliferation Assay:  
 
Cell proliferation was measured using the MTS-PMS colorimetric assay that 
produces a colored formazan product in the presence of phenazine 
methosulphate that absorbs at 470 nm.  Wild type and stably transfected A431 
cells were trypsinized, neutralized, and counted.  Approximately 2x103 cells were 
seeded in quadruplicate in 8 different 96 well plates to cover from day 0 to day 7.  
Plates from each daily time point were washed (2x) with HBSS solution.  Cells 
were subsequently incubated with a mixture of 100 μl of phenol red free RPMI 
and 20 μl of MTS-PMS reagent for 2 hour at 37°C.  The absorbance was 
measured at 470nm.  Data taken are significant where p< 0.05 by student t test. 
2.11 Colony Formation Assay: 
 
1.5x103 cells were seeded in 60 mm petri-dishes in triplicate.  Medium was 
changed every 3 days.  Colony formation was visualized and the assay was 
terminated before the edges of colonies came into contact.  Cells were washed 
(3x) with 1X PBS, followed by fixation with 3.7% formalin for 15 minutes.  Fixed 
cells were stained with 0.5% crystal violet for 30 minutes, washed with distilled 
water  to remove all extra stain,  and air dried.  The colonies were visualized 
under the microscope and counted.  Quantitative measurements were obtained 
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by measuring dye extracted from cells with 10% acetic acid and comparing 
absorbance measurements at 570 nm. 
2.12 Cell Adhesion Assay: 
96-well plates were coated with laminin at 37
o
C for 1 hour and were washed 
twice with washing buffer.  Uncoated wells served as negative controls.  Plates 
were blocked with blocking buffer at 37
o
C in 5% CO
2 
for 45-60 minutes, and 
subsequently washed with washing buffer and chilled on ice.  5x10
4
/ml cells in 
100 μl were added to each well, and Incubated in 5% CO
2 
at 37
o
C for 30 
minutes.  Unbound cells were removed by shaking the plate at 2000 rpm for 10-
15 seconds, followed by 2-3 washes with washing buffer.  Adherent cells were 
fixed with 4% paraformaldehyde at RT for 10-15 minutes, washed with washing 
buffer, stained with Crystal Violet for 10 minutes, and finally washed with water.  
Plates were turned upside down and air dried completely.   Cells were incubated 
in 10% Acetic acid at RT for 30 minutes and the extracted dye was quantified at 
an absorbance of 570 nm.  Data taken are significant as p< 0.05 by student’s t 
test. 
2.13 Soft Agar Colony Formation: 
 
Soft agar colony formation assays were performed in 60 mm plates, coated with 
a bottom layer of 1% agar in 2X RPMI medium.  The upper layer was prepared 
by mixing 1×103 A431 transfectant cells with 0.8% agarose in 2X RPMI-10% FBS 
medium.  Liquid RPMI-10% FBS medium was added on top of the agar layers 
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and replaced weekly.  The assay was performed in triplicate.  Plates were 
stained with 0.5% crystal violet solution, and colonies were counted and 
photographed. 
2.14 Animal Study:  
 
Athymic nude mice (Athymic nude-Foxn1nu nude, 5–6 weeks old) were obtained 
from Harlan Laboratories, (Haslett, MI), and housed in micro-isolator cages. 
IACUC approval was obtained for all experiments.  The animals involved were 
provided care in accordance with Wayne State University’s Animal Investigation 
Committee (AIC) guidelines.  The animals were allowed to adapt for 1 week 
under sterile conditions.  Xenografts were established by injecting 3×106 
exponentially growing A431-GR16 or A431-EV stable cells in 100 μl HBSS 
(Hanks balanced salt solution) subcutaneously with no Matrigel.  The tumor size 
was measured by vernier caliper every three days, and the tumor volume was 
computed and reported in cc from the formula for an ellipsoid body (volume = 
length × breadth × height × π /6), where for small tumors, height (= thickness) 
was assumed to correspond to the smaller of the two diameters.  At the end of 
the experiment, mice were sacrificed, and tumors excised, shock-frozen in liquid 
N2, and stored at –80°C for further analysis.   
2.15 Tissue Analysis- RNA and Protein Isolation: 
Fresh tissue was homogenized using MagNA Lyser (Roche Applied Science) 
according to the protocol consisting of 2 pulses for 29 seconds at 3000 rpm 
separated by 90 seconds of cooling.  Total RNA was extracted from the frozen 
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tissues using Nucleospin RNAII isolation kit, according to the manufacturer's 
instructions.  One microgram of total RNA was reverse-transcribed to a single 
strand cDNA in a final volume of 20 μL in two steps according to the 
manufacturer's instructions (Applied Biosystems).  In the first step, a pre-mix with 
RNA, random primers, dNTPs, and water were denatured at 70°C for 5 minutes.  
In the second step, SuperScriptTM III Reverse Transcriptase (Cat. No. 18080-093, 
Invitrogen), buffer, DTT, and RNase inhibitor were added and left for 5 minutes at 
room temperature, followed by heating for 60 minutes at 55°C, 15 minutes at 
70°C, and 5 minutes at 95°C.  All reagents were obtained from Invitrogen.   
Relative mRNA quantification was performed using a fluorescence-based real-
time detection method with Applied Biosystems 7500 real time Fast Sequence 
Detection System.  Oligonucleotide primers and probes for VEGF, BAX, Bcl2, 
HIF-1 and β-actin gene were purchased from Applied Biosystems. A 12-μL 
reaction mixture containing 2.5 μL of cDNA template, 6.25 μL TaqMan Universal 
PCR master mix (Cat. No. 4326708, Applied Biosystems), and 0.62 μL primer 
probe mixture was amplified using the following thermal cycler parameters: 
incubation at 50°C for 2 minutes and denaturation at 95°C for 10 minutes, 
followed by 40 cycles of the amplification step (denaturation at 95°C for 15 
seconds and annealing/extension at 60°C for 1 minute).  All amplification 
reactions were performed in triplicates.  The β-actin gene was used as 
endogenous control.  Data taken are significant; p < 0.05 by student’s t test. 
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CHAPTER 3 : Results 
3.1 Domain mapping of the cytoplasmic tail of β4 that interacts 
with 12-LOX in tumor cells 
Our initial studies demonstrated by yeast two-hybrid screen that 12-LOX interacts 
with the C-terminus of β4 integrin (Tang, Finley et al. 2000).  Furthermore, we 
showed that 12-LOX translocates to the cell membrane on β4 stimulation with 
laminin or 3E1 (β4 stimulating antibody) where its interaction with β4 leads to 
increased 12-LOX activity and 12(S)-HETE production (Tang et al., unpublished 
observation).  Therefore we sought to determine the structural basis for the 
functional interaction between the integrin  β4 subunit and 12-LOX.  The 
cytoplasmic tail of the β4 integrin subunit (~1,007 aa) is uniquely large among 
known β4 subunits (~50 aa) (Giancotti and Tarone 2003).  It includes two pairs of 
fibronectin type III (FNIII) domains, separated by a 143-amino acid linker 
segment (Hogervorst, Kuikman et al. 1990; Suzuki and Naitoh 1990).  The first 
pair of FNIII repeats, FN1 and FN2, spans aa residues 1126 – 1315 of the β4 
cytoplasmic tail.  Using a panel of bacterial expression plasmids that yield 
recombinant protein in E.coli and mammalian expression constructs that express 
various mutant forms of the β4 cytoplasmic tail for the interaction study (Figure 
3.1), we were able to delineate the β4 domain necessary for 12-LOX interaction.  
We chose to start the analysis using pGR38 (L), pGR39 (F3, F4, C), pGR40 (F1, 
F2, L, F3), pGR45 (F1, F2, L), pGR46(TM, F2), pGR47(TM, C) as these GFP 
fusion constructs contain overlapping fragments of the cytoplasmic tail of β4 
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integrin. Utilizing fluorescence activated cell sorting (FACS), a pool of GFP-
positive cells were selected.    We confirmed the expression of β4 mutants as 
GFP-fusion proteins by Western blot and then performed co-immunoprecipitation 
on whole cell lysates to determine the interaction of 12-LOX with various β4 
mutants.  As shown in Figure 3.1A, 12-LOX is able to bind to fusion proteins, 
expressed by pGR40 (Tx40), pGR45 (Tx45), pGR46 (Tx46), and pGR47 (Tx47), 
but not to the fusion protein with only the linker region, pGR38 (Tx38).  Weak 12-
LOX binding to the fusion protein encoded by pGR39 (Tx39) was observed.  All 
the above mutants that show strong binding have 22 residues (aa 1126-1315) in 
common, which suggested the presence of a strong binding site(s) for 12-LOX, 
located in the region spanning these residues 1126 – 1315 of the β4 cytoplasmic 
tail.  
3.2 Identification of integrin β4 macro domains important for 
12-LOX interaction 
Integrin α6β4 exists on the cell surface and forms part of a large complex 
containing numerous growth factor receptors, tetraspanins and other molecules 
that influence the approach to study this integrin.  The minimum functional unit 
for targeting β4 into hemidesmosomes and controlling the cellular distribution of 
plectin is contained within the first two type III fibronectin domains (FN1 and FN2) 
plus the 1st 37 residues of the connecting segment.  Therefore this region may 
have potential binding motifs that contribute either directly or indirectly to binding 
its target proteins (Litjens, de Pereda et al. 2006).  After we identified the region 
spanning FN1-FN2 (Figure 3.1A) within β4 as containing a putative 12-LOX-
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interaction domain, we began assessing sub-domains of this region (Figure 
3.2A).   The expression construct pRC-CMV, a generous gift from Dr. Filippo 
Giancotti (Memorial Sloan-Kettering Cancer Center, NY), contains the full-length 
β4 subunit cDNA (Giancotti, Stepp et al. 1992)  and was used to make deletions 
in the region we identified, namely aa 1126 – 1315 of the β4 cytoplasmic tail.  
These also received a myc-tag insertion (Figure 3.2A and 3.2B).  The Myc tag 
was introduced so as to differentiate between β4 deletion mutants and full length 
β4 integrin.  We have confirmed that there is no interference of this Myc tag with 
binding to 12-LOX (data not shown).  Using these deletion mutant co-
immunoprecipitation studies were performed to identify the structural 
determinants responsible for the physical interaction between 12-LOX and β4 
integrin.  CHO cells were co-transfected with β4 deletion mutants in combination 
with 12-LOX and the expression of both proteins was confirmed by Western blot 
using Myc and 12-LOX antibody (Figure 3.2D).  The co-immunoprecipitation 
results revealed that 12-LOX interacts with the FN1 domain in β4, as binding was 
unaffected by the absence of FN2 (ΔFN2-β4) (Figure 3.2C).  However, in the 
absence of FN1, binding was markedly attenuated (ΔFN1-β4) (Figure 3.2C and 
3.3D).  Also the treatment with β4 stimulating antibody (3E1) showed no effect on 
the interaction.  The mass spectrometry results show an increase in 12(S)-HETE 
production in cells expressing the ΔFN2-β4 that retains FN1 domain  while 12(S)-
HETE production was attenuated in the absence of the FN1 domain (ΔFN1-β4) 
(Figure 3.2E).  Data shown is statistically significant,∗ p < 0.05 by student t test 
when comparing HETE production of 12L+ΔFN1 in presence of AA with 
55 
 
 
12L+ΔFN2 and 12L+ β4.  While it shows no significance comparing 12L+ΔFN2 
and 12L+ β4.  Thus, from the above results we conclude that β4-FN1 is crucial 
for β4 integrin interaction with 12-LOX. 
3.3 Micro-domain mapping of integrin β4-FN1 region necessary 
for 12-LOX interaction 
After determining that the FN1 domain (aa 1126-1215) of the cytoplasmic tail of 
β4 encodes a 12-LOX binding element, we generated Myc-tagged constructs 
with successive micro deletions (32 aa each) within this putative FN1 domain 
(Figure 3.3A).  Primers were designed accordingly and β4 deletion constructs 
(ΔFN01-β4, ΔFN02-β4 and ΔFN03-β4) were generated (Figure 3.3A).  These 
expression constructs were then co-transfected in CHO cells along with 12-LOX 
vectors.  Protein expression from the constructs was confirmed by detection with 
Myc mAb (Figure 3.3C) as well as 12-LOX.  Subsequently co-
immunoprecipitation results showed that when the FN01 domain is deleted, 
binding with 12-LOX is hindered (Figure 3.3B).  Over-expression of the proteins 
led to immunoprecitation that was independent of the 3E1 stimulus but specific to 
the constructs. Thus we confirmed that this 32 amino acid region between 
residues 1126-1157, is critical for β4 interaction with 12-LOX. 
 
3.4 Fine-mapping of integrin β4-FN01 domain 
Fine mapping was performed within the FN01 (1126-1157, 32 aa residue) 
domain to identify the residues relevant for 12-LOX -β4 protein interaction.  The 
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FN01 region was divided further into three parts and deletion mutants were 
generated.  The β4 deletions [ΔFN01-1, (aa 1126—1136); ΔFN01-2, (aa 1137—
1147); and ΔFN01-3, (aa 1148—1157)] constructs were co-transfected with 12-
LOX in CHO cells and their respective expression was confirmed by Western 
blot. Expression of β4 micro-domain deletion mutants and also full length β4 
were detected with β4-450-11A antibody specific for the cytoplasmic domain of 
integrin β4, and were reprobed with 12-LOX pAb and actin mAb for actin loading 
control (Figure 3.4B).  Co-immunoprecitation studies were performed using the 
whole cell lysates of these transfectants (Figure 3.4C).  12-LOX antibody was 
used to pull down 12-LOX and the immunoblots were detected with β4 450-11A 
mAb.  The result revealed weak interaction of integrin β4 with 12-LOX in absence 
of the FN01-2 micro-domain (Figure 3.4C). Stimulation of β4 with 3E1 did not 
affect the interaction. Thus, we have identified the 10 amino acid region (aa 
1137-1147) within integrin β4 that is required for interaction and activation of the 
12-LOX enzyme. 
3.5 Mutations of important phosphorylation sites within the      
FN01 sub domain affect the interaction of full length β4 
with 12-LOX 
 A predictive algorithm was used to locate the putative phosphorylation sites 
S1140, S1151, and Y1157 within the FN01 sub domain of full length β4 (Figure 
3.5A).  Of these three, S1140 is within the region of interest that is important for 
12-LOX interaction.  Single point mutations were made in these phosphorylation 
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sites by changing serine amino acids to alanine, and tyrosine to phenylalanine.  
In addition, we also mutated Y1494 as it has been shown to be a major 
regulatory signaling site and also plays an important role in promoting cancer 
progression (Dutta and Shaw 2008).  The mutations were confirmed by 
sequencing and these β4 phosphorylation mutant constructs were co-transfected 
with 12-LOX into CHO cells.  Western blots whole cell lysates were probed with 
β4 mAb 450-11A that is specific for the cytoplasmic domain of integrin β4.  Blots 
were successfully reprobed with 12-LOX and actin (Figure 3.5B). 
Immunoprecitation of 12-LOX was performed on cell lysates from these 
transfectants and co-immunoprecipitated β4 was again detected with 450-11A 
mAb.  The results show that the S1140A mutation in β4 weakens the interaction 
with 12-LOX, while Y1157F and Y1494F markedly reduce the interaction 
compared to wild-type β4 binding (Figure 3.5C, lane 6).  From the above results 
we incur that S1140, Y1157 and Y1494 are important phosphorylation sites that 
impact the interaction of full length β4 with 12-LOX. 
3.6 12-LOX phosphorylation is important for activity but not 
interaction 
In previous studies we have shown that 12-LOX and β4 association is 
functionally relevant and results in an increase in 12-LOX enzymatic activity as 
measured by HPLC where 12(S)-HETE biosynthesis was increased following cell 
stimulation with β4 mAb 3E1 (Tang et al., unpublished observation).  We have 
also shown that the cytoplasmic domain of β4 integrin can interact specifically 
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with phosphorylated Src (pSrc) after β4 integrin ligation in A431 cells. The 
ligation of β4 integrin induces Src activation, which resulted in tyrosine 
phosphorylation of 12-LOX (Dilly et al., to be published).  Here we show that 
treatment with Src inhibitor PP2 (5 μM) leads to decreased 12-LOX activity as 
measured by 12(S)-HETE production.  CHO transfectant cells were stimulated 
with 3E1 stimulating antibody followed by treatment with PP2 inhibitor 
concentration of (5 μM) for 1 hour.  Arachidonic acid (10 μM) substrate is added 
and incubated for 6 hours.  Medium was analyzed for 12(S)-HETE by using the 
LC/MS (Figure 3.6).   Thus, the interaction between 12-LOX and β4 is 
independent of 3E1 stimulus in CHO cells but activity is dependent on 3E1 
stimulus, which leads to phosphorylation of 12-LOX via Src.  Data shown above 
is significant, as,*, p < 0.05 by student t test when comparing 12L+β4-PP2 with 
12L+β4 and also the 3E1 treated set of 12L+β4 with 12L+β4-PP2.   
3.7 Ectopic expression of GR16 (FN1 and FN2 region) blocks 
full length β4 and 12-LOX interaction 
The A431 human epidermoid carcinoma cell line endogenously expresses 12-
LOX and β4.  Therefore, we used A431 to perform a competition assay using the 
plasmid construct pGR16 that encodes the Myc-tagged FN1 and FN2 portion 
(residues 1126-1315) of the full length β4 integrin (Figure 3.1).  In addition to 12-
LOX and integrin β4, the expression of GR16 (FN1 and FN2), in A431 
transfectants was confirmed by Western blot (Figure 3.7A).  Myc antibody was 
used to detect the GR16 fragment of β4 integrin (23 kDa) and 12-LOX pAb for 
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12-LOX (78 kDa) and β4 -450-11A for full length β4 integrin (β4 ∼200 kDa).  Actin 
mAb was used for actin loading control.  A431 (pGR16) cell lysates were 
immunoprecipitated with a polyclonal antibody against 12-LOX and 
immunoblotted for, the Myc tag of GR16 and also full length integrin β4.  As 
shown in Figure 3.7A, when ectopically expressed in A431 cells, the GR16 
region (FN1and FN2) interacts with 12-LOX competitively inhibiting the 12-LOX- 
β4 interaction (Figure 3.7B, lane2).  The lack of detectable interaction between 
12-LOX and full-length β4 integrin is not due to any change in β4 expression 
(Figure 3.7A), but is due to the competition by the GR16 region (FN1 and FN2) 
(Figure 3.7B).  Endogenous levels of Myc (115 kDa, faint band) are not 
detectable in Western blots since the signal for β4- Myc construct is very strong. 
Thus, the results suggest that the β4 FN1-FN2 region, encoded by pGR16, is 
able to block the interaction between 12-LOX and full-length β4 integrin in a 
dominant negative manner. 
3.8 Ectopic expression of GRFN01-2 (1137-1147) competes 
with GR16 (1126-1315) or full length β4 and blocks the 
interaction with 12-LOX to ∼ 50% 
From the previous section it is clear that GR16 (FN1 and FN2) fragment 
competes with full length β4 and blocks the interaction with 12-LOX.   Since the 
fine mapping shows that the FN01-2, 11 aa fragment (residues 1137-1147) of β4 
is important for interaction, we used this fragment to compete with either GR16 or 
full length β4.  We transfected, CHO cells with triple constructs expressing 
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GRFN01-2, GR16 and 12-LOX  or GRFN01-2, β4 and 12-LOX individually and 
then made recombinant lysates. The individual lysates from cells transfected with 
GRFN01-2 and 12-LOX were combined with lysates from cells expressing GR16 
or full length β4.  Expression of all transfected constructs, GR16 (Myc tagged, 23 
kDa), 12-LOX (78 kDa), and full length β4 integrin (∼ 200 kDa) is shown in Figure 
3.8A by Western blot. GR-FN01-2, Myc-tagged construct (1 kDa) expression is 
not shown on the blot due to the size constraint.  Co-immunoprecipitation of 
these cell lysates with 12-LOX and blot detection with Myc antibody shows that 
GRFN01-2 reduced the interaction with GR16 (Figure 3.8B).  Similarly 
immunoblot with β4 antibody showed reduction in 12-LOX interaction with full 
length β4 in the presence of GR-FN01-2 (Figure 3.8B).  The β4 integrin FN01-2 
domain encoded by pGRFN01-2 binds to 12-LOX competes with GR16 (aa 
1126-1315), and full length β4, and reduces the interaction between 12-LOX and 
GR16 or full length β4 integrin.  Endogenous level of Myc (115 kDa, faint band) is 
not detectable due to strong signal of the GR16-Myc construct. 
3.9 Ectopic expression of GR16 decreases cell migration 
 
After confirming that GR16 could block the biochemical interaction of 12-LOX 
with the full length β4 integrin subunit, we focused on the functional aspect of this 
association.  12-LOX and β4 integrin have both been shown to play a role in the 
migration of tumor cells.  The sole metabolic product of 12-LOX metabolism of 
arachidonic acid, 12(S)-HETE, can modulate several parameters related to the 
metastatic potential of tumor cells like cell motility and cell invasion (Timar, Silletti 
et al. 1993; Honn, Tang et al. 1994).  The α6β4 integrin has a significant role in 
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signaling pathways of epithelial and carcinoma cells leading to enhanced 
migration and invasion (Mercurio and Rabinovitz 2001).  We have reported 
previously that β4 stimulation leads to 12-LOX membrane translocation in A431 
cells.  Additionally, we also showed that 12-LOX activity may be important for 
α6β4-dependent cell migration on laminin following EGF stimulation (Tang et al., 
unpublished observation).  Therefore we examined the effect of ectopic 
expression of GR16 on A431 cell migration through a transwell insert in the 
presence and absence of β4 stimulation.  The A431 stable transfectant 
expressing the β4 fragment GR16 shows 40% less cell migration compared to 
parental A431 and A431-EV (Figure 3.9).  Addition of 12(S)-HETE to the A431-
GR16 stable transfectant rescued cell migration.  This shows that 12-LOX activity 
resulting from β4 interaction is important for cell migration.  Also the data shown 
in figure 3.9 is significant, *, p < 0.05, comparing cell invasion of A431-GR16 with 
A431 wild-type and A431-EV cells.  Migration of A431-GR16 with 12(S)-HETE 
add back was similar to A431-EV. 
3.10 Ectopic expression of GR16 decreases 12-LOX activity 
 
The arachidonate metabolite 12(S)-HETE, the sole product of 12-LOX activity, 
induces a plethora of responses in tumor cells and is linked to tumor progression 
and metastasis (Honn, Tang et al. 1994; Gao and Honn 1995; Nie, Tang et al. 
2000; Nie, Tang et al. 2000).  We have reported previously that 12-LOX and β4 
association is functionally relevant and shows an increase in 12-LOX enzymatic 
activity by HPLC where 12(S)-HETE biosynthesis was increased following cell 
stimulation with β4 mAb 3E1 (Tang et al., unpublished observation).  Therefore, 
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in this study we measured the 12-LOX enzymatic activity after blocking the 
interaction of 12-LOX with full length β4 by ectopic expression of β4 fragment 
GR16.  Arachidonic acid was administered for 6 hours to parental A431 cells and 
A431 transfectants.  Following incubation, conditioned medium from cell cultures 
was processed as described and 12(S)-HETE production was measured.  The 
results from the mass spectrometry analysis reveal a significant decrease in 
12(S)-HETE production when the interaction between 12-LOX and full-length β4 
is blocked by GR16 (A431-GR16) compared to the A431-EV stable transfectant 
(Figure 3.10).  Thus ectopic expression of β4 fragment GR16 can effectively 
reduce 12-LOX activity.  Data shown is significant since, *, p < 0.05 by student t 
test there is significant decrease in 12-LOX activity in A431-GR16 stable 
transfectant when compared to A431-EV or A431 wild-type. 
 
3.11 Ectopic expression of GR16 decreases cell proliferation 
Competitive inhibition of the association between 12-LOX and β4 with the GR16 
fragment resulted in reduced cell migration and 12-LOX activity compared to 
parental A431 cells or A431-EV stable transfectants.  Consequently the reduction 
in 12(S)-HETE production should result in reduced cell proliferation, as we and 
others have shown that 12(S)-HETE is mitogenic.  Moreover, the α6β4 integrin 
triggers signaling pathways involved in cell differentiation, adhesion, invasion and 
metastasis (Giancotti and Ruoslahti 1999; Gleason, Adley et al. 2005).  Likewise, 
12(S)-HETE affects cell proliferation, motility, invasion, angiogenesis, and inhibits 
apoptosis (Nie, Hillman et al. 1998).  One possible integrator of these 12(S)-
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HETE signaling mechanisms in tumor cells is the pleiotropic transcription factor 
NF-ĸB, which controls cell proliferation and apoptosis and was shown in PC-3 
cells, to be activated by over expression of the platelet-type 12-LOX or 
exogenously added 12(S)-HETE  (Kandouz, Nie et al. 2003) .  Therefore, we 
examined if cell proliferation was affected when 12-LOX is blocked by GR16 
fragment of β4 integrin.  We performed an MT-PMS assay to study cell 
proliferation.  We seeded 2 x 103 A431 stable transfectants expressing GR16 or 
EV into a 96 well plate.  The cells were seeded in triplicate in 8 plates starting 
from day-0 to day-7.  There is significant decrease in cell proliferation in A431-
GR16 stable transfectant when compared to A431-EV everyday over the period 
of 6 days. The seventh day results show that here was 30% reduction in cell 
proliferation in the A431-GR16 stable transfectant compared to EV (Figure 3.11).  
Data shown is significant, *, p < 0.05, by student t test. 
3.12 Ectopic expression of GR16 reduces colony formation 
The functional relevance of using GR16 to block the interaction of 12-LOX with 
full length β4 integrin is significant, as it reduced 12-LOX enzymatic activity, cell 
migration and cell proliferation.  Therefore we decided to perform an in vitro cell 
survival assay using colony formation assay.  We have shown previously 12-LOX 
activity increases by interaction with β4 integrin (Tang et al., unpublished 
observation).  The 12-LOX metabolite 12(S)-HETE acts as a survival factor in 
many tumor cells involving a complex signaling mechanism leading to 
tumorgenesis (Samuelsson 1983; Honn, Tang et al. 1994).  We seeded A431-
GR16 and A431-EV stable transfectant cells in 60 mm plates.  The assay was 
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terminated after 7 days before the edges of colonies came into contact.  The 
colonies were counted under microscope using10 fields/ plate.  The average 
colony count for A431-EV was 35-45 colonies per field (20-30 cells/colony), while 
it was only 20-25 colonies per field for A431-GR16 (15-20 cells/colony) (Figure 
3.12A).  There is significant decrease in cell colony formation in A431-GR16 
stable transfectant when compared to A431-EV.  Further quantitative analysis 
showed 40% less colony formation with A431-GR16 stable transfectant cells 
(Figure 3.12B).  Data shown is significant, *, p < 0.05, by student t test.  
3.13 Ectopic expression of GR16 and its interaction with 12-LOX 
shows no effect on full length β4 cell adhesion function 
Integrins are heterodimeric receptors mediating adhesion of cells to extracellular 
matrices and other cells (Buck and Horwitz 1987; Ruoslahti and Pierschbacher 
1987; Ginsberg, Loftus et al. 1988; Springer 1990; Hynes 1992).  α6β4 integrin is 
a basement membrane receptor for laminin and an important component of 
hemidesmosomes where it mediates adhesion of epithelial cells to underlying 
basement membrane (Kajiji, Tamura et al. 1989; Carter, Kaur et al. 1990; De 
Luca, Tamura et al. 1990; Sonnenberg, Linders et al. 1990; Sonnenberg, Linders 
et al. 1990; Sonnenberg, Calafat et al. 1991; Lee, Lotz et al. 1992).  Above we 
have shown that, we could successfully block the interaction of full length β4 
integrin with 12-LOX by ectopically expressing the GR16 fragment.  However, 
this appeared to have no effect on the cell adhesion function of β4 integrin 
(Figure 3.13).  A431 wild type cells and the A431 transfectants ectopically 
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expressing GR16 or empty vector cells were plated on the laminin coated 96 well 
plates and the cell adhesion was quantified by measuring the absorbance of 
stained cells at 550 nm.  The results showed no difference in cell adhesion 
between A431 wild type and A431 transfectants.  Since, *, p > 0.05, by student t 
test.     
3.14 Ectopic expression of GR16 suppresses tumor growth in 
an animal model (in vivo study) 
In this study we show that the interaction between 12-LOX and β4 mediates the 
invasive role of α6β4 integrin in the growth of carcinoma.  When this interaction 
is blocked using the β4 fragment GR16 we saw a decrease in the tumor growth 
in vivo.  The athymic nude mice were separated into 2 groups.  The control group 
(n=6) was subcutaneously injected with A431-EV and the test group (n=6) with 
A431-GR16 stable transfectant cells.  We evaluated the xenograft tumor growth 
after the A431 cell inoculation every 3 days for 4 weeks.  The tumor growth 
progression in the test group showed delay (day3 onwards till day15 where it 
plateaus) compared to the control group and the average tumor volume of the 
test group was comparatively smaller in size to the control group (Figure 3.14).  
Thus the data suggest that when the 12-LOX- β4 interaction is blocked by the β4 
fragment GR16, tumor growth is reduced.  These results support our in vitro data 
that interference of this interaction reduced cell migration, 12-LOX activity, and 
cell proliferation.  A431-GR16 shows significantly reduced tumor weight, since, *, 
p < 0.05, by student t test. 
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3.15 Tumor tissue analysis for Real time PCR for gene 
expression (in vivo study) 
Real time PCR was performed on tumor tissue cDNA using Taqman primers and 
reagents using actin as the house keeping gene.  Bcl2, an anti-apoptotic gene is 
elevated in most cancers.  Results from our laboratory have previously shown 
that the Bcl family of proteins is involved in apoptosis during 12-LOX inhibition in 
rat Walker-256 carcinoma cells (Tang, Chen et al. 1996).  When 12-LOX specific 
antisense oligonucleotides were transfected, W526 cells underwent apoptosis; 
there was a decrease in Bcl2 and therefore a decrease in Bcl2: Bax ratio. Over 
expression of Bcl2 protein partially overcame apoptosis (Tang, Chen et al. 1996) 
Also the Pidgeon et al. study showed a similar decrease in Bcl2 levels and the 
reduction was coupled to an increase in Bax levels when cells were treated  with 
12-LOX inhibitor (Pidgeon, Kandouz et al. 2002).  Inhibition of 12-LOX-β4 
interaction with GR16 translated to a similar shift in the Bcl2: Bax ratio.  The 
relative gene expression of Bcl2 decreased while that of Bax increased in A431-
GR16 transfectants tumor tissue samples compared to the A431-EV tumor tissue 
samples (Figure 3.15A and 3.15B).   
VEGF is a potent tumor angiogenesis factor.  Agents that target VEGF 
and its signaling pathways inhibit tumor growth and propagation in various 
experimental models (Ferrara 2002).  12-LOX and 12-HETE both have been 
known to play a role in angiogenesis (Gao and Honn 1995; Nie, Hillman et al. 
1998; Nie, Tang et al. 2000; Nie, Tang et al. 2000) as well as increase the 
surface expression of αvβ3 integrin (Honn, Tang et al. 1994).  Residue Y1494 of 
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β4 integrin regulates VEGF expression and stimulates angiogenesis, thus 
contributing to tumor progression (Dutta and Shaw 2008).  Therefore, we 
examined what, if any, effect GR16 would have on VEGF production. In tumor 
tissue samples expressing A431-GR16 transfectants compared to A431-EV,  the 
relative expression of VEGF is significantly decreased in the presence of the 
GR16 fragment of β4 (Figure 3.15C).  This was also confirmed by 
immunostaining for VEGF.  The data shown is significant from Figure 3.15 A, B 
and C, as,*, p < 0.05, by student t-test when comparing the A431-GR16 group to 
A431-EV which indicates there is increase in apoptosis and a significant 
decrease in angiogenesis. 
The tissue slide from A431-GR16 transfectants showed less staining for 
VEGF compared to A431-EV control slide (Figure 3.16).  VEGF expression is 
regulated by a variety of transcription factors.  The promoter region of the VEGF 
gene has binding sites for transcription factors like Sp1/Sp3, AP-2, Egr-1, STAT-
3, and HIF-1 (Pages and Pouyssegur 2005).  Of these factors, HIF-1 is 
responsible for transcriptional regulation under hypoxic conditions (Forsythe, 
Jiang et al. 1996; Krishnamoorthy, Jin et al. 2010) and our group has shown that 
12-LOX regulates HIF-1α (Krishnamoorthy, Jin et al. 2010).  
Therefore we examined the effect of GR16 on HIF-1α expression (Figure 
3.15D).  While the relative levels of HIF-1α was decreased in tumors from GR16 
transfectants, this was not very significant since the, *, p > 0.05, from student t 
test.  The increased angiogenicity of A431-EV transfectants was also confirmed 
by immunostaining and RT-PCR for VEGF.  Expression of GR16 protein (23 
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kDa) was confirmed by Western blot and was present in tumor tissue samples 
from the A431-GR16 transfectant group (Figure 3.17).  
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Figure 3.1:  Schematic representation of β4 integrin.   
 
 
 
 
 
 
 
 
 
 
 
Table 3-1: List of bacterial and mammalian expression constructs of β4 
fragments. Bacterial plasmids encode the HIS-tag under control of the T7 
promoter.  Mammalian expression constructs are either Myc-tagged or EGFP-
tagged and are regulated by the CMV promoter.  TM, transmembrane; IC, 
intracellular; F1, F2, F3, and F4 are fibronectin type III repeats. 
Courtesy: Dr. Gerhard Wiche 
NOTE: Elsewhere F1, F2, F3, F4 are labeled as FN1, FN2, FN3, and, FN4 
respectively. 
  
CF4F3LF2F1ICTM
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Figure 3.1A: Co-immunoprecipitation shows 12-LOX binds with the fusion 
proteins expressed by pGR40 (Tx40), pGR45 (Tx45), pGR46 (Tx46), and pGR47 
(Tx47), but not with pGR38, pGR39, or pEGFP (TxG).  Immunoprecipitation was 
done using pAb against 12-LOX and antibody mAb GFP was used to detect β4 –
GFP fusion fragments.  10% SDS gel was run at 130V at 4°C and transferred to 
nitrocellulose membrane at 0.4A for 1.5 hours at 4°C.  The binding site localizes 
to amino acids 1126 – 1315 of the cytoplasmic tail. L: Linker, F: FN, TM: 
Transmembrane, C: Cytoplasmic 
Source: Preliminary data for grant, experiment performed by Dr. Keqin Tang. 
Reprinted with permission. 
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Figure 3.2: Mapping of integrin β4 macro domains necessary for 12-LOX 
interaction. 
Whole cell lysates were immunoprecipitated with 12-LOX antibody and probed 
for β4 mutants with Myc antibody.  Blots were stripped and reprobed for 12-
LOX.   (A) Schematic of integrin β4 sub-domains.  (B) Description of deleted 
sub-domains in the cytoplasmic tail of β4 integrin.  (C) Co-immunoprecipitation 
experiments from CHO cells transiently transfected with ΔFN1-β4 or ΔFN2-β4 
constructs.  12-LOX was pulled down with pAb 12-LOX antibody and the 
immunoblots were probed with mAb for Myc.  10% SDS gel was run at 130V at 
4°C and transferred to nitrocellulose membrane at 0.4A for 1.5 hours at 4°C 
(D) Western blot of whole cell lysates showing expression of ΔFN1-β4, ΔFN2-
75 
 
 
β4 (upper) and 12-LOX constructs (middle) in transiently transfected CHO cells 
along with actin control (lower).  pAb 12-LOX, mAb Myc and actin antibodies 
were used to detect 12-LOX and β4 deletion constructs.  (E) 12-LOX activity 
measured as a function of 12(S)-HETE production by mass spectrometry with 
β4 mutant constructs   ΔFN1 and ΔFN2.  Data are statistically significant,∗ p < 
0.05 by student t test when comparing 12(S)-HETE production of 12L+ΔFN1 in 
presence of AA with12L+ΔFN2 and 12L+ β4, while it shows no significant 
difference when comparing 12L+ΔFN2 and 12L+ β4. 
Note: In (B) and (C) images on the right are overlays to show molecular 
weight marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
A     
1126-1221
EC TM IC FN1 FN2 L FN3 FN4 C
EC TM IC FN01 FN02 FN03 FN2 L FN3 FN4 C
EC TM IC Myc FN02 FN03 FN2 L FN3 FN4 C
EC TM IC FN01 Myc FN03 FN2 L FN3 FN4 C
EC TM IC FN01 FN02 Myc FN2 L FN3 FN4 C
FN01 deletion (∆FN01)
FN02 deletion (∆FN02)
FN03 deletion (∆FN03)
 
 
 
 
Number of deleted 
amino acids 
MW: 194,997 Da ; full length -
β4  
ΔFN01-β4 32 aa (1126—1157) 191,576; (+myc192,779) 
ΔFN02-β4 32 aa (1158—1189) 191,259; (+myc192,462) 
ΔFN03-β4 32 aa (1190—1221) 191,501; (+myc192,704) 
 
 
FN1 Sequence: FN01 -32 aa, FN02- 32 aa, FN03- 32 aa 
FN01-S  Q  P  P  P  H  G  D  L  G  A  P  Q  N  P  N  A  K  
A  A  G  S  R  K  I  H  F  N  W  L  P  P   
 
FN02-S  G  K  P  M  G  Y  R V  K  Y  W  I  Q  G  D  S  E  S  
E  A  H  L  L  D  S  K  V P  S  V  E 
 
FN03-L  T  N  L  Y  P  Y  C  D  Y  E  M  K  V  C  A  Y  G  
A  Q  G  E  G  P  Y  S  S  L  V  S  C  R  T 
 
 
77 
 
 
 
B
IP Ab     : 12-LOX
WB Ab   : Myc (β4-tag)
192kDa192kDa
IP Ab     : 12-LOX
WB Ab   : Myc (β4-tag)
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Figure 3.3:  Mapping of micro-domains within integrin β4-FN1 region necessary 
for 12-LOX interaction.  12-LOX interacts with the FN01 sub-domain within the 
FN1 macro-domain, and maps to residues 1126-1157.  (A) Schematic of integrin 
β4 macro-domains (B) Co-immunoprecipitation  of 12-LOX in CHO cells  
transiently transfected with β4 deletion mutants, ΔFN01, ΔFN02 and ΔFN03 
shows that there is no binding of 12-LOX with ΔFN01, while its binding was 
unaffected by ΔFN02  and ΔFN03.  12-LOX antibody was used to pull down 12-
LOX and the immunoblots were detected with mAb Myc.  10% SDS gel was run 
at 130V at 4°C and transferred to nitrocellulose membrane at 0.4A for 1.5 hours 
at 4°C (C) Western blot of whole cell lysates showing expression of β4 deletion 
mutants, ΔFN01, ΔFN02, ΔFN03, and 12-LOX constructs in transiently 
transfected CHO cells along with the actin control.  Constructs were detected 
with Myc antibody for β4 deletion mutants, and 12-LOX pAb for 12-LOX, and 
actin mAb was used for the actin loading control. 
Note: In (B) and (C) images on the right are overlays to show molecular 
weight marker. 
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Strip and reprobe with 12-LOX Antibody: 
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Figure 3.4:  Fine-mapping of integrin β4 domains.  P-12-LOX interacts with the 
FN01-2 micro-domain and maps to residues 1137-1147.  (A) Schematic of β4 
integrin micro sub-domains.   (B) Western blot of whole cell lysates showing 
expression of β4 micro-domain deletion mutants ΔFN01-1, ΔFN01-2, ΔFN01-3 
and 12-LOX constructs in transiently transfected CHO cells along with the actin 
control.  Integrin β4 constructs, and full length β4 were detected with β4-450-11A 
antibody (against the cytoplasmic domain of integrin β4), while 12-LOX pAb was 
used to detect 12-LOX, and actin mAb was used for the actin loading control.  (C) 
Co-immunoprecipitation with β4 micro-domain deletion mutants ΔFN01-1, 
ΔFN01-2, and ΔFN01-3 constructs in transiently transfected CHO cells, shows 
no binding of 12-LOX with β4 mutant ΔFN01-2, while it shows binding with 
ΔFN01-1 and ΔFN01-3.  12-LOX antibody was used to pull down 12-LOX and 
the immunoblots were detected with β4 450-11A mAb. 10% SDS gel was run at 
130V at 4°C and transferred to nitrocellulose membrane at 0.4A for 1.5 hours at 
4°C. 
Note: In (B) and (C) images on the right are overlays to show molecular 
weight marker. 
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Figure 3.5:  Phosphorylation sites in the FN01 domain of integrin β4 necessary 
for 12-LOX interaction.  12-LOX interacts with the FN01 sub-domain in FN1, 
within in a region spanning residues 1126-1157.  (A) Schematic of predicted 
important phosphorylation sites to be mutated.  (B) Western blot of whole cell 
lysates showing expression of β4 mutants, S1140A, S1151A, Y1157F, Y1494F, 
and 12-LOX constructs in transiently transfected CHO cells along with actin 
control.  β4-450-11A mAb (against the cytoplasmic domain of integrin β4) was 
used to detect β4 phosphorylation mutants while 12-LOX was detected with 12-
LOX pAb and actin mAb for the actin loading control.  (C) Co-
immunoprecipitation of 12-LOX from CHO cells transiently transfected with β4 
phosphorylation mutants.  The β4 mutants S1140A, Y1157F and Y1494F show 
weak or no binding with 12-LOX, while S1151A shows no effect on interaction.   
12-LOX antibody was used to pull down 12-LOX and the immunoblots were 
probed with β4 450-11A mAb.  10% SDS gel was run at 130V at 4°C and 
transferred to nitrocellulose membrane at 0.4A for 1.5 hours at 4°C. 
Note: In (B) and (C) images on the right are overlays to show molecular 
weight marker. 
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Figure 3.6:  12-LOX phosphorylation is important for activity.  Mass spectrometry 
measurements of 12-LOX activity from CHO transfectant cells.  12(S)-HETE 
production is elevated in CHO cells co-transfected with 12-LOX and β4 integrin 
and is enhanced when transfectants are stimulated with 3E1.  Treatment with 
Src-family inhibitor PP2 (5 μM) for 2 hours attenuates activity.  Data shown 
above are significant, *, p < 0.05  when comparing 12L+β4 –PP2 with 12L+β4,  
and also the 3E1 treated set of 12L+β4 with 12L+β4-PP2.   
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Figure 3.7:   The β4 integrin region GR16, encoding FN1 and FN2 domains (aa 
1126-1315 in pGR16) binds to 12-LOX and blocks the interaction between 12-
LOX and full length β4 integrin.  (A) A431 cells were transiently transfected with 
the expression construct pGR16.  Western blot of whole cell lysates shows the 
expression of GR16 (Myc-tagged), 12-LOX and β4 integrin.  Myc antibody was 
used to detect the GR16 fragment of β4 integrin (23 kDa) and 12-LOX pAb for 
12-LOX (78 kDa) detection and β4 -450-11A for full length β4 integrin (∼200 
kDa).  Actin mAb was used for the actin loading control.  (B) Cell lysates were 
immunoprecipitated with a polyclonal antibody against 12-LOX and 
immunoblotted for the Myc tag of GR16 (target band ∼ 23 kDa), or full-length β4 
integrin (target band, ∼205 kDa) and also 12-LOX (78 kDa).  10% SDS gel was 
run at 130V at 4°C and transferred to nitrocellulose membrane at 0.4A for 1.5 
hours at 4°C.  Endogenous Myc (115 kDa) band is below the level of detection 
unless figure contrast is increased. 
Note: In (A) and (B) images on the right are overlays to show molecular 
weight marker. 
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Reprobe with β4 Antibody 450-11A: 
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Reprobe with 12-LOX antibody 7225: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8:  The β4 integrin FN01-2 domain (residues 1137-1147), encoded by 
pGRFN01-2, binds to 12-LOX, competes with GR16 (1126-1315) and full length 
β4, and reduces the interaction between 12-LOX and GR16 or full length β4 
integrin. CHO cells were transiently transfected with the expression construct 
pGRFN01-2, pGR16, β4, and, 12-LOX in different combinations.  (A) Western 
blot of whole cell lysates shows the expression of all transfected constructs, 
GR16 (Myc tagged, 23kDa), 12-LOX (78 kDa), full length β4 integrin (∼ 200 kDa) 
and actin loading control (42 kDa). Note: Expression of GR-FN01-2 is not shown 
here as 1 kda band is not visible. (B) Cell lysates were immunoprecipitated with 
pAb against 12-LOX and immunoblotted for Myc (target band ∼ 23 kDa), or full-
length β4 integrin (target band, ∼205 kDa). 12-LOX was also confirmed.   10% 
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SDS gel was run at 130V at 4°C and transferred to nitrocellulose membrane at 
0.4A for 1.5 hours at 4°C. 
Note: In (A) and (B) images on the right are overlays to show molecular 
weight marker. 
Figure (B) , Due to quenching of β4 probe, covered myc signal so digital 
camera picks β4. 
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Figure 3.9:  Cell migration and invasion assay using parental A431 cells and the 
A431-GR16 stable cell line.  A431-GR16 shows 40% less migration compared to 
A431-EV and parental A431.  Add back of 12(S)-HETE rescued A431-GR16 cell 
migration.  (A) Quantitative colorimetric analysis (OD570) of the migrated cells, (B) 
Bright field images of transwell migrated cells stained with Diff-Quick at 100X 
magnification.  Data shown are significant, *, p < 0.05, comparing cell invasion of 
A431-GR16 with A431 wild-type and A431-EV cells. 
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Figure 3.10:   LC-MS measurements of 12-LOX activity from an A431 stable cell 
line expressing the GR16 construct or pCDNA3.1 -empty vector (EV). 
The cells were treated with 10 μM AA for 6 hours and the medium was collected.  
The samples were processed as described in Methods and subjected to mass 
spectrometry.  A431-GR16 significantly attenuates 12(S)-HETE production 
compared to A431-EV.  Data shown are significant, *, p < 0.05. 
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Figure 3.11:   Cell proliferation assay (MT-PMS assay).  A431-GR16 or A431-EV 
cells were seeded in a 96 well plate and assayed every day for 6 days.  The 
reading was measured at absorbance 470 nm.  There is a 30% reduction in cell 
proliferation when 12-LOX is blocked by the GR16 fragment of β4 integrin (Gray) 
compared to EV (purple).  Data shown are significant, *, p < 0.05, by student t 
test; there is a significant decrease in cell proliferation in the A431-GR16 stable 
transfectant when compared to A431-EV everyday over the period of 6 days. 
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Figure 3.12:  Colony formation assay.  1.5 x 103 cells either A431-GR16 or A431-
EV cells were plated in triplicate in 60 mm plates and grown for 7 days.  (A) The 
colonies were stained with crystal violet and photographed.  Ten fields per plate 
were counted with bright field microscopy.  (B) Quantification of cell-associated 
crystal violet was done by destaining the colonies and reading the absorbance at 
570 nm.  There is a 30% reduction in colony formation when 12-LOX is blocked 
A431-EV A431-GR16 
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by the GR16 fragment of β4 integrin compared to EV.  Data shown are 
significant, *, p < 0.05, by student t test.  There is significant decrease in cell 
colony formation in the A431-GR16 stable transfectant when compared to A431-
EV. 
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Figure 3.13:  Cell Adhesion Assay.  Parental A431, or transfectant A431- GR16 
or A431-EV cells were plated in triplicate 5 x103 cells on laminin-coated 96 well 
plates and incubated for 1 hour.  Adherent cells were fixed and stained with 
crystal violet.  Absorbance was measured at 570 nm by destaining the cells with 
10% acetic acid.  The results show no difference in cell adhesion function when 
12-LOX is blocked by the GR16 fragment of β4 integrin compared to EV and 
parental A431.  There is no significant difference between samples since, *, p > 
0.05, by student t test.  There is no significant change in cell adhesion in the 
A431-GR16 stable transfectant when compared to A431-EV and A431 wild-type. 
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Figure 3.14:  Decreased tumor growth in GR16 transfected A431 cells.  (A) 
Growth kinetics of tumors derived from mice with A431 transfectants over a 
period of 3 weeks shows decreased growth in mice with the GR16 fragment 
compared to EV.  Data shown are statistically significant, *, p < 0.05, by student t 
test.  A431-GR16 shows significantly reduced tumor growth compared to the 
A431-EV group over the period of 4 weeks.  (B) Tumors are attenuated ∼ 2 fold 
in mice receiving A431-GR16, encoding the competitive binding fragment of β4 
integrin, (C) Tumors excised from mice with A431-GR16 are half the size and 
weight compared to A431-EV.  Data shown are statistically significant, *, p < 
0.05, by student t test.  A431-GR16 shows significantly reduced tumor weight. 
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Figure 3.15:  Real time PCR results from cDNA samples of tumor tissue, 3 tumor 
tissue samples per group were analyzed.  (A) Relative expression of anti-
apoptotic gene Bcl2 is higher in A431-EV compared to A431-GR16.  (B)  Relative 
expression of angiogenesis marker gene VEGF is higher in A431-EV compared 
to A431-GR16.  (C)  Relative expression of pro apoptotic gene BAX is higher in 
A431-GR16 compared to A431-EV.  (D) The difference in the relative expression 
of the HIF1 gene in A431-GR16 and A431-EV is not very significant since the, *, 
p > 0.05, from student t test.  The data shown are significant in A, B and C, as,*, 
p < 0.05, by student t-test when comparing the A431-GR16 group to A431-EV, 
which indicates there is an increase in apoptosis and a significant decrease in 
angiogenesis. 
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Figure 3.16:  Immunohistochemical staining with VEGF antibody showing brown 
Immunostaining for VEGF of A431 transfectant tumor tissue samples 
(magnification 40X).  A431- GR16 (A) shows less VEGF staining compared to 
A431-EV (B), indicative of more angiogenesis in A431-EV, which is blocked by 
the presence of the GR16 fragment.  Data are based on the evaluation of 3 
sections in each group and a similar trend was observed in all samples. 
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Figure 3.17:  Western blot results of protein derived from the homogenized tumor 
tissue from 8 mice showing the expression of Myc-tagged GR16 (23 kDa) in 
A431-GR16 (A), and its absence in control mice injected with A431-EV 
transfectants (B). 10% SDS gel was run at 130V at 4°C and transferred to 
nitrocellulose membrane at 0.4A for 1.5 hours at 4°C.  Myc mAb was used to 
detect the GR16 fragment of β4 integrin.  Endogenous Myc (115 kDa) is present 
in all blots as a faint band 115 kDa. 
Note: In (A) and (B) images are overlays to show molecular weight marker. 
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CHAPTER 4 : Discussion 
4.1 Discussion 
 
Evidence from previous studies has shown that enzymes from the AA pathway of 
eicosanoid biosynthesis, such as cycloxgenase and lipoxygenase, play important 
roles in cancer progression and metastasis (Honn, Tang et al. 1994; Yamamoto, 
Suzuki et al. 1997).   Lipoxygenases are involved in various cancers including 
prostate, breast, pancreatic, and lung cancer.  They have been recently identified 
in ovarian cancer (Chang, Liu et al. 1993; Kim, Gu et al. 1995; Krieg, Kinzig et al. 
1995; Natarajan, Esworthy et al. 1997; Nie, Hillman et al. 1998; Ding, Kuszynski 
et al. 1999; Timar, Raso et al. 1999; Aran, Bryant et al. 2011; Guo, Liu et al. 
2011).  The AA metabolite, 12(S)-HETE,  was shown to be involved in various 
cellular functions important in the metastatic cascade of tumors such as survival, 
adhesion, invasion and motility as well as angiogenesis,  due to fact that 12-LOX 
is involved in variety of signaling pathways (Honn, Tang et al. 1994; Tang, Chen 
et al. 1996; Trikha, Timar et al. 1997; Tang, Nie et al. 1999; Nie, Tang et al. 
2000; Krishnamoorthy, Jin et al. 2010; Krishnamoorthy and Honn 2011). 
Therefore, given the wide distribution of P-12-LOX in various human cancers 
(Honn, Tang et al. 1994) and its correlation with pathologic stage and grade 
(Gao, Grignon et al. 1995), and the effects elicited by its metabolite, 
understanding the regulation of this enzyme may have important therapeutic 
regulations. The physical interaction between 12-LOX and β4 was first identified 
through yeast two-hybrid screening, confirmed by co-immunoprecipitation in 
A431 cells, and further recapitulated by ectopically expressed 12-LOX and the 
112 
 
 
cytoplasmic tail of β4 integrin in CHO or PC-3 cells (Tang, Finley et al. 2000).  
Another yeast two hybrid study identified CLP, DTRAP-1, and, the ∆K12H4.8 as 
potential interacting partners and regulators of 5-LOX (Provost, Samuelsson et 
al. 1999).  The direct interaction between 5-LOX and CLP has been 
demonstrated to inhibit actin polymerization and to interfere with the binding of 
CLP to F-actin (Provost, Doucet et al. 2001).  Similarly, our group has shown 
direct interaction of 12-LOX with β4 integrin and also has demonstrated that 
extracellular stimulation of β4 by 3E1 in A431 cells subsequently triggers a 
signaling mechanism that recruits 12-LOX to the cytoplasmic domain of β4 and 
also increases 12-LOX activity (Tang et al., unpublished observation).  The 
uniquely long cytoplasmic domain of the β4 integrin subunit protein has been 
implicated in connecting the α6β4 integrin complex with the cytoskeletal 
elements via cytoplasmic components of hemidesmosomes (Schwarz, Owaribe 
et al. 1990; Spinardi, Ren et al. 1993; Borradori and Sonnenberg 1996).  The 
distal regions of the β4  tail have been implicated in interactions with plectin and 
the other major hemidesmosomal components BPAG1 and BPAG2 (Wilhelmsen, 
Litjens et al. 2006).  In this study we have defined for the first time the region in 
the cytoplasmic tail of β4 critical for interacting with 12-LOX.  CHO cells were 
used to carry out these interaction studies as they express α6 but not β4 and 12-
LOX.   We performed domain mapping  by making deletion mutants of β4 integrin  
and  co-transfecting them with 12-LOX in CHO cells and looking for the loss of 
interaction.  Co-immunoprecitation studies revealed  that the FN01-2 (1136 -1147 
aa) domain in the cytoplasmic tail of β4 integrin is critical for interacting with 12-
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LOX.  Residues 1137-1147 span a portion of the FN1 region of β4 integrin that is 
within the first FNIII repeat.  Until now not much has been known about this FN1 
region and no important interactions have been characterized.  The first tandem 
pair of FNIII domain has been reported to provide a high level of insight that 
should facilitate structure-function studies (de Pereda, Wiche et al. 1999).   The 
other fibronectin pairs have been reported to be involved in protein binding.   FN2 
domain has been known to interact with the hemidesmosomal components such 
as plectin, BPAG1, and BPAG2.  In a similar study, Biffo et al, showed that 
p27BBP interacts with β4 integrin in vivo thus linking β4 integrin to intermediate 
filament cytoskeleton.  A yeast two-hybrid screen using β4 cytodomain confirmed 
the interaction.  Both by yeast two-hybrid and in vitro assay they showed that 
p27BBP  interacts with the two NH2 -terminal FNIII region that is important for 
hemidesmosome formation and also signaling (Biffo, Sanvito et al. 1997).  Many 
phosphorylation sites have been located in the connecting segment (CS) and 
FNIII pair 3 and 4, which when phosphorylated by Src family kinase (SFK) leads 
to recruitment of Shc and Shp2 mediating downstream signaling (Dans, 
Gagnoux-Palacios et al. 2001; Shaw 2001; Bertotti, Comoglio et al. 2006).  
Recent studies have identified Y1494 as an important phosphorylation site on β4 
integrin for signaling and promoting tumor development and progression (Dutta 
and Shaw 2008).  We made point mutations in the most important 
phosphorylation sites as predicted by internet tool, Netphos; S1140, S1151, 
Y1157, and double mutation S1151+Y1175 within the FN01 region and also 
Y1494 as mentioned in literature (Dutta and Shaw 2008).  S1140 and Y1157 
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when mutated show weak binding with 12-LOX when compared to S1151 
mutation and full length β4 and the double β4 mutants, S1151+Y1157 (changed 
to A1151+F1157) which show strong interaction with 12-LOX.  Interestingly 
Y1494 mutation, shown previously to play an important role in tumor progression, 
resulted in loss of interaction between 12-LOX and β4.  Thus, we infer from these 
results that tyrosine mutations play an important role. S1140, Y1157 and Y1494 
are potentially important phosphorylation sites that hinder the interaction of 12-
LOX with integrin β4.  We have shown that FN01-2 (11aa, 1137-1147 residues) 
is important for interaction with 12-LOX; the S1140 phosphorylation site is within 
the region of interest while both the tyrosine sites which hinder the interaction are 
located outside this region.  Even these sites, located at a distal end are able to 
have an impact on the interaction which of 12-LOX and β4 which demonstrated 
their potential role in cancer progression.  Shaw et al have already shown Y1494 
as the master phosphorylation site in β4 and its role in tumorgenesis.  
Interestingly when the region (11aa, 1147-1157) containing this phosphorylation 
site Y1157 is deleted we still see interaction of integrin β4 with 12-LOX.   This 
may be because of structural stability of the integrin β4 on deletion of this region.  
The other possibility may be it leads to exposure of the FN01-2 region (11aa, 
1137-1147), which makes it more accessible for 12-LOX.  Proteins have complex 
3D structure that makes it difficult to answer this question.   Designing 
experiments to study the role of this phosphorylation site Y1157 would help us to 
better understand this inconsistency. 
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The interaction of 12-LOX with β4 or the β4 deletion mutants when over 
expressed in CHO cells was found to be independent of 3E1 stimulus.   
Furthermore, mass spectrometry data for 12-LOX activity revealed that these 
interactions were able to induce increased 12(S)-HETE production in the 
presence of extracellular stimuli.  Our lab has also shown that β4 integrin ligation 
regulates 12-LOX activity through c-Src kinase (Dilly et al., Unpublished data).  
Treatment with Src- family kinase inhibitor PP2, showed decrease12-LOX activity 
on integrin ligation indicating Src phosphorylation is important for 12-LOX activity. 
     Furthermore, we have shown that GR16 (FN1 and FN2), fragment of β4 
integrin is sufficient to block the interaction of 12-LOX with full length β4 in A431 
cells.  The A431 cell line is well characterized with respect to its expression of 
α6β4 integrin and 12-lipoxygenase protein.  There are numerous papers in the 
literature documenting the role of α6β4 integrin in A431 cell motility and invasion.  
Previously we have shown that the cytoplasmic tail of β4 was able to block the 
interaction of 12-LOX with full length β4 (Tang K., et al unpublished observation).  
Here we have shown that the β4 fragment called β4-GR16 about 23 kD size 
(∼200 aa) consisting of FN1 and FN2 region when stably transfected in A431 
cells could block the interaction of 12-LOX and full length β4.  This β4-GR16 
fragment interacts with the 12-LOX may be in the cytoplasm even before its 
translocation to the membrane.  Also we showed that GR-FN01-2 (1137-1147, 
11 aa fragment of β4) could compete with GR16 and full length β4 to interact with 
12-LOX, thus confirming that the 11 aa acid region GR-FN01-2 is important for 
interaction with 12-LOX.  
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It has been previously demonstrated that β4 integrin plays an important 
role in tumorogenesis and tumor progression (Lipscomb and Mercurio 2005).  
Our studies have previously shown that 12-(S)HETE protects tumor cells from 
apoptosis and stimulates invasion, motility and angiogenesis  (Honn, Tang et al. 
1994; Gao and Honn 1995; Tang, Renaud et al. 1995; Nie, Tang et al. 2000; Nie, 
Tang et al. 2000) as well as increases integrin expression (Tang, Grossi et al. 
1993) .  Studies have reported that suppression of integrins affects downstream 
eicosanoids, indicating integrins  indirectly  regulate eicosanoids.  For example, 
Mitchel K. et al have shown that  suppression of integrin α3β1 in breast cancer 
cells reduces COX-2 gene expression and inhibits  tumorigenesis.  They showed 
COX-2 as the downstrean effector of α3β1  in tumor cells  (Mitchell, Svenson et 
al. 2010).  Recent studies by Chuang JY. et al have shown connective tissue 
growth factor (CTGF), binds to integrins and inhibits COX-2 expression and cell 
motility in oral cancer through signal transduction pathways that involve FAK, 
PI3K, Akt and c-Jun (Chuang, Yang et al. 2011). We have for the first time shown 
that an  integrin can directly interact and regulate an  eicosanoid enzyme, namely 
12-LOX  (Tang et al , unpublished observation).  The impact of blocking this 
interaction was seen in 12-LOX activity, cell migration, and cell proliferation and 
tumor growth.  In this study we have not only  mapped the domain of β4 
cytoplasmic tails that inteacts with 12-LOX but we have also shown that,  12-LOX 
activity,  and cell migration is regulated by  integrin interaction with 12-LOX. 
As mentioned above, 12(S)-HETE induces a plethra of cellular responses  
in tumor cells.  It is shown to protect tumor cells from apoptosis and induce 
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invasion, motility, and angiogenesis (Honn, Tang et al. 1994; Gao and Honn 
1995; Nie, Tang et al. 2000; Nie, Tang et al. 2000; Nie, Tang et al. 2000; Guo, 
Liu et al. 2011) as well as surface expression of αvβ3 integrin (Tang, Grossi et al. 
1993).  We previously showed  that β4 ligation mediates translocation of 12-LOX 
from the cytosol to the membrane and interacts with β4 integrin.  This interaction 
causes the increase in  12-LOX activity  which results in increased 12-(S)HETE 
production (Tang et al , unpublished observation).  In this study we have shown 
here that when interaction of the full length β4 integrin and 12-LOX is blocked by 
the ectopically  β4 fragment GR16,  there is 40% reduction in 12-LOX activity  
and exogenous addition of 12-HETE rescues the activity.  
Several studies have shown chemotactic factors such as EGF stimulate 
rapid dissembly of hemidesmosmes  in cells with rapid coincident with formation 
of lamilipodia and membrane ruffles (Rabinovitz, Toker et al. 1999). 
Phosphorylation of β4 cytoplasmic domains increases in response to stimuli such 
as EGF and PMA, both of which dissemble hemidesmosomes  .  It is reported 
that activation of PKC –α  plays an important  role in  phosphorylation of the 
cytoplasmic tail but also in dissembly of hemisdesmosomes (Rabinovitz, Toker et 
al. 1999; Dans, Gagnoux-Palacios et al. 2001).  Our group has also shown that 
ligation of β4 integrin likely contributes to cell migration via the phosphorylation of 
12-LOX and subsequent production of 12(S)-HETE (Dilly A. et al., to be 
submitted) and also reported that 12-LOX also plays a role in cell migration 
(Tang et al., unpublished observation).  Migration of A431 cells stimulated with 
laminin or commercially available β4 stimulating antibody (3E1) following 
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treatment with EGF was reduced in the presence of BMD 122, a select P-12-LOX 
enzymatic inhibitor.  Additionally exogenously added 12(S)-HETE has been 
shown to stimulate tumor cell motility, invasion and migration, endothelial cell 
retraction, release of proteases, and processes dependant on PKC activation 
(Liu, Marnett et al. 1994; Liu, Khan et al. 1995) 
in the present study, we showed that  when 12-LOX  interaction with β4 
integrin is blocked by the β4 fragment GR16, there was a 40% reduction in cell 
migration and cell proliferation.  Addition of exogenous 12(S)-HETE  rescued the 
cells and increased migration of the A431 –GR16 cells similar  to A431-EV stable 
transfectant cells.  Also we have shown decreased cell proliferation and colony 
formation. 
We believe that the β4 fragment GR16 functions as a dominant negative 
by interacting with 12-LOX in the cytosol and preventing it’s binding to native, full-
length, membrane-associated β4 and thereby prevents 12-LOX activation.  In 
support of this observation, when A431 stable transfectant cells ectopically 
expressing the β4 fragment GR16 were injected subcutaneously into athymic 
nu/nu mice, there was a significant decrease in tumor growth when compared to 
A431 stable transfectant cells expressing the empty vector. 
 12(S)-HETE has been shown to protect tumor cells from apoptosis and 
induce angiogenesis (Honn, Tang et al. 1994; Gao and Honn 1995; Nie, Tang et 
al. 2000; Nie, Tang et al. 2000) as well as surface expression of αvβ3 integrin 
(Tang, Grossi et al. 1993). In W256 cells, apoptosis induced by antisense 
oligonucleotides, and 12-LOX inhibitors was followed by a rapid down regulation 
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of Bcl-2 protein, and thus a dramatic decrease in the Bcl-2/Bax ratio that could be 
suppressed by Bcl-2 over-expression (Tang, Chen et al. 1996). A study by 
Pidgeon et al. showed a similar decrease in Bcl-2 levels response to Baicalein or 
BHPP and the reduction was coupled to increase in Bax levels (Pidgeon, 
Kandouz et al. 2002).  The results suggest that the P-12-LOX pathway plays an 
important physiological role in regulating apoptosis (Tang, Chen et al. 1996).  
Our RT-PCR data show decreased expression of Bcl-2 in murine tumors of 
A431-GR16 transfectants where the interaction of 12-LOX with full length β4 is 
blocked.  Immunostaining with CD31 antibody, which detects the presence of 
endothelial cells, showed that the vascular networks in tumors derived from 
A431-EV transfectant cells were sinusoidal in pattern and well- developed in 
structure.  In contrast, in tumors derived from A431-GR16 cells, endothelial cells 
were present but were randomly distributed and did not form an organized 
vascular network.  The increased angiogenicity of A431-EV transfectants was 
also confirmed by RT-PCR for VEGF gene expression and brown 
immunostaining of tumor tissues for VEGF.  12(S)-HETE is known to increase 
the surface expression of αvβ3 integrin, an integrin predominantly associated 
with angiogenic blood vessels in tumors and human wound tissue in both rat 
aorta endothelial cells and murine pulmonary micro-vascular endothelial cells 
(Honn, Tang et al. 1994), (Brooks, Clark et al. 1994).  12-HETE also acts as a 
mitogen for micro-vascular endothelial cells at low concentration of serum (Tang, 
Diglio et al. 1995).  In a  study by Nie et al., they showed that 12-LOX transfected 
PC3 cells have enhanced  tumor angiogenicity in a mouse model; and a similar 
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study on breast cancer by Conolly and Rose found that 12-LOX over-expression 
enhanced tumor angiogenesis in a fat pad animal model (Connolly and Rose 
1998; Nie, Hillman et al. 1998).  Thus, 12(S)-HETE and 12-LOX appear to act as 
potent angiogenesis enhancers in cancer cells.  VEGF and bFGF (basic 
fibroblast growth factor) are known to elevate expression and activation of 
various integrins that are involved in angiogenesis (Klein, Bikfalvi et al. 1996; 
Byzova, Goldman et al. 2000).  Shaw et al. have shown that phosphorylation 
state of residue Y1494 of β4 integrin is important for VEGF expression and 
stimulates angiogenesis thereby contributing to tumor progression (Dutta and 
Shaw 2008).  Thus, β4 signaling domain is also known to drive VEGF- mediated 
retinal neo-vascularization (Nikolopoulos, Blaikie et al. 2004).   Pharmaceuticals 
that disrupt β4 signaling have been sought as useful therapy agents, for VEGF 
driven retinal neo-vascularization and angiogenesis (Giancotti 2007).  Our RT-
PCR data show decreased VEGF expression when the interaction of 12-LOX 
with full length integrin is blocked in A431-GR16 transfectant tumor cells.  
 This additional data supports our hypothesis that 12-LOX association with 
membrane-bound native β4 alters 12-LOX activity resulting in increased cellular 
migration, and proliferation while the fragment of β4 that contains the 12-LOX 
binding motif, can be used to prevent this interaction. 
Integrins are known to predominantly signal through recruitment and 
activation of Src- family kinases.  Dilly et al have recently shown that Src kinase 
activity is required for β4 integrin mediated regulation of 12-LOX, which may in 
turn regulate metastatic potential of cancer cells (Dilly et al, unpublished data). 
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Most integrins recruit FAK through their β subunit.  As well as activating signaling 
through PI3K to AKT / protein kinase B (PKB) through phosphotidylinositol-3, 4, 
5-triphosphate (PtdIns (3, 4, 5) P3), FAK functions as a recruiter of Src to focal 
adhesions.  Src phosphorylates CAS which recruits Crk-Doc-180 complex 
thereby activating Rac which further activates PAK, JNK, JUN and NFkB.  FAK 
also activates extracellular signal regulated  kinase (ERK) and mitogen activated 
protein kinase  (MAPK).  Certain integrins α5β1, α1β1, αvβ3 are coupled to SFKs 
such as Fyn and Yes through α subunits (Miranti and Brugge 2002; Schwartz 
and Ginsberg 2002; Giancotti and Tarone 2003; Guo and Giancotti 2004) 
Signaling of β4 function has been studied and has been shown that it contains 
multiple tyrosine phosphorylation sites in its cytoplasmic tails thus it behaves as 
binary RTK (Mainiero, Pepe et al. 1995; Mainiero, Murgia et al. 1997; Gagnoux-
Palacios, Dans et al. 2003).  α6β4 can directly interact with Src, phosphorylating 
five major tyrosine phosphorylation sites thereby activating Ras- ERK/MAPK  and 
PI3K signaling (Mainiero, Pepe et al. 1996; Shaw, Rabinovitz et al. 1997; Dans, 
Gagnoux-Palacios et al. 2001).  These pathways activated through SFK are 
sufficient to induce cell migration, cell survival and proliferation.  Both SFK 
mediated tyrosine phosphorylation and PKC mediated serine phosphorylation of 
β4 cytotail prevents assembly of hemidesmosome, thus opposing its 
cytoskeleton bonding(Dans, Gagnoux-Palacios et al. 2001; Rabinovitz, Tsomo et 
al. 2004).  Interestingly β4 also combines with several RTKs, including EGF-R, 
ErbB2, Met and Ron (Mariotti, Kedeshian et al. 2001; Santoro, Gaudino et al. 
2003; Guo, Pylayeva et al. 2006).  Apart from its classical signalling pathway it 
122 
 
 
also has been shown that integrin signalling is mediated  by 12-LOX  by various 
researchers (as mentioned below). 
Pidgeon et al demonstrated that over-expression of platelet-type 12-LOX 
in prostate cancer PC3 cells or epithelial cancer A431 cells significantly extended 
their survival and delayed apoptosis when cultured under serum-free conditions 
by affecting the expression and localization of the vitronectin receptors, αvβ3 and 
αvβ5, in PC3 and A431 cancer cell lines (Pidgeon, Kandouz et al. 2002). 
The study by Yeung et al showed that inhibition of 12-LOX or PKC 
resulted in inhibition of dense granule secretion and attenuation of both, αIIbβ3 
aggregation and activation.  However, activation of PKC downstream of 12-LOX 
inhibition rescued agonist-induced aggregation and integrin αIIbβ3 activation. 
Further, inhibition of 12-LOX had no effect on PKC-mediated aggregation 
indicating that 12-LOX is upstream of PKC (Yeung, Apopa et al. 2012).  Also it 
has been observed that the expression of platelet type 12-lipoxygenase 
upregulated Integrin αv mRNA and showed increased angiogenesis in 
esophageal squamous cell carcinoma (ESCC) 
(http://www.rescancer.com/stomach-cancer/32887.html, FEB 2012).   
One  recent study have shown that suppression of  α6β4 in breast cancer 
cells reduced  cycloxgenase -2 gene expression and also inhibits tumorogenesis, 
and invasion . Thus they showed a novel role for COX-2 as a downstream 
effecter of α3β1 in tumor cells, thereby identifying  potential therapeutic target to 
inhibit breast cancer  (Mitchell, Svenson et al. 2010).  Dilly et al  have recently 
shown 12-LOX is regulated through  β4 integrin via Src activation, which may in 
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turn regulate metastatic potential of cancer cells (Dilly et al, unpublished data).  
Similarly by expressing GR16 or using a commercial  11 aa small peptides, 
crossbinding to the 12-LOX binding domain and we can suppress full length β4 
integrin  interaction with 12-LOX as a potential therapeutic target for cancer 
therapy. 
Collectively our previous studies in combination with the novel findings 
here show that  12- LOX and β4 interaction enhances cell motility, invasion, and 
increases activity leading to  tumor progression (Tang et al., unpublished 
observation). However when this interaction is blocked  by using this small 11 aa 
fragment, we were able to reduce tumor progression by reducing cell motility, 
invasion and 12-LOX activity.  Validation of these observations using the in vivo 
model confirms the functional relevance of blocking 12-LOX and β4 interaction.  
Further studies are required to understand the potential role of this interaction in 
assembly or disassembly of hemidesmosomes in cancer progression.  The work 
presented in this study has established a new conceptual framework with 
significant implications for carcinomas and other pathologies that involve β4 
integrin signaling through 12-LOX.  This study has provided a novel target for 
therapeutic intervention and has revealed a new dimension in integrin and 
eicosanoid biology. 
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Figure 4.1: Schematic overview of the study.  We have demonstrated that the 
interaction of 12-LOX with full length β4 can be blocked with β4 fragment that 
decreases 12-LOX activity, cell invasion, cell proliferation and also attenuates 
tumor growth.  This represents a novel therapeutic target. 
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ABSTRACT 
 
A DEFINED DOMAIN OF INTEGRIN SUBUNIT β4 DETERMINES INTERACTION 
WITH 12-LOX AND PLAYS A ROLE IN TUMOR PROGRESSION. 
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Degree:       Doctor of Philosophy 
A yeast two-hybrid screen and subsequent studies identified the 
cytoplasmic tail of β4 integrin as a 12-Lipoxygenase (12-LOX)-interacting protein.  
The physical interaction of β4 with 12-LOX regulates 12-LOX activity and leads to 
cell migration, which suggests that 12-LOX interacts both physically and 
functionally with β4 to promote cancer progression.  Here we describe for the first 
time the critical interaction domains that unite β4 integrin and 12-LOX. The amino 
acid residues spanning 1126-1157, correspond to a domain in the cytoplasmic 
tail of β4 that is important for 12-LOX binding and activation.   
Expressed fragments of the β4 (FN1 and FN2) domains are sufficient to 
block the interaction of 12-LOX with full length β4 leading to decreased cell 
survival, cell migration, and proliferation and tumor growth.  These domains 
represent novel therapeutic targets.   
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